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One of the most cited papers in both Scopus and CrossRef, is by John Ioannidis et al 1. The paper, 
titled ‘Why Most Published Research Findings Are False’, evaluated the reproducibility of medical 
papers published in the previous decade. It argued that individual positive research findings 
depend massively on the pre-test probability. What matters is the totality of the evidence, rather 
than any individual results.  
Reproducibility refers to the precision of the results of tests carried out under changing 
conditions of measurement 2. These changing conditions may refer to different times of testing, 
locations, populations tested, or laboratory instruments used. This may be relevant in cases 
where different laboratory assays are available, for instance, or to assess biologic variability over 
different weeks. It is often confused with repeatability, which is a measurement of closeness of 
agreement between successive measurements carried out in the same manner, or over a very 
short period of time 2. It is thought of as testing the test procedure itself. The reproducibility of 
research findings in equine medicine needs to be carefully evaluated given the often small sample 
sizes and limited populations tested. 
A second influential paper was published in the Mayo Clinic Proceedings in 2013 3. This evaluated 
all original papers published in the New England Journal of Medicine over a 10-year period. In 
total, there were 146 medical reversals during this time, including C-reactive protein testing for 
sepsis, and knee arthroscopy for osteoarthritis. 
The relevance for laminitis is that many reversals in our understanding of underlying causes of 
the disease have occurred over the last two decades. Fifteen years ago, hypercortisolaemia was 
thought responsible for many of the clinical signs of PPID 4 and carbohydrate-mediated 
gastrointestinal dysfunction was thought the major pathophysiologic contributor to pasture-
associated laminitis .  
It behooves us to continue to validate prior research findings, and always to question dogma 5. 
vii 
Abstract 
The objectives of this study were 1) to evaluate the adrenocorticotropic hormone (ACTH) 
response to thyrotropin releasing hormone (TRH) administration at different times of the year 
and in different locations, 2) to determine the effects of insulin dysregulation testing on ACTH 
concentrations and 3) to determine the reproducibility of two tests of insulin dysregulation. 
For the first objective, 13 healthy horses in Perth and 29 in Townsville were identified by clinical 
parameters and normal monthly endogenous plasma ACTH. TRH-stimulation tests were 
performed at two time points during the circannual pituitary cycle at both sites. Perth horses 
were sampled at 10 minutes post-TRH (T10) and Townsville horses were sampled at 30 minutes 
post-TRH (T30).For the second and third objectives, a group of 15 healthy Thoroughbred and 
Standardbred horses underwent oral sugar tests (OST) and two-step insulin response tests (IRT) 
three times, at weekly intervals. For one week, endogenous ACTH was measured at the basal and 
testing time points in this group and in an additional control group of 15 horses. 
For the TRH-stimulation tests, the T10 or T30 time point ACTH concentrations were significantly 
higher during the dynamic phase of the circannual pituitary cycle at each site, compared to during 
the dynamic phase (Perth T10 p=0.001; Townsville T30 p<0.0001). The mean T10 ACTH 
concentration in Perth during the dynamic phase was 248.5 pg/mL (range 80.7 - 511 pg/mL and 
95% CI 170.2 - 326.9 pg/mL). The mean T30 ACTH concentration in Townsville during the dynamic 
phase was 112.3 pg/mL (range 53.6 – 227.0 pg/mL and 95% CI 93.4 - 131.2 pg/mL). For the OST, 
no substantial increase in insulin concentrations was observed. There was insufficient agreement 
of the test results between weeks. There was no statistical difference in ACTH concentrations 
before and at the 60 minutes post-sugar time point (p = 0.27). For the IRT, there was insufficient 
agreement between glucose concentrations at 25, 30 and 35 minutes post-insulin.  There was 
insufficient agreement of the test results between weeks. There was no statistical difference in 
ACTH concentrations before and at 30 minutes post-insulin (p = 0.5).  
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Chapter 1. Literature review 
1.1 Laminitis 
Laminitis is a significant cause of morbidity and mortality in horses 6,7. It is a painful and 
debilitating condition of the equine foot that can lead to chronic morbidity, loss of use, and 
compromised welfare 8. It occurs in association with pasture access (or other causes of high non-
structural carbohydrate {NSC} intake) 9. It can also occur in association with critical illness 10,11 
and contralateral lameness (i.e. support limb laminitis) 12 which are thought to have differing 
aetiologies and pathophysiologies . As such, only pasture-associated laminitis will be discussed 
herein. 
 
Clinical signs of laminitis are referable to those of foot pain, namely increased digital pulse 
amplitude or pulse pressure difference, hoof heat and pain on hoof tester application, along with 
characteristic lameness and stance alterations 13. The disease is usually bilateral in the forelimbs 
but may affect any foot 14. The clinical signs are due to laminar injury, stretching and subsequent 
failure 15, with secondary distal phalangeal rotation and/or sinking. Previous laminitis can be 
recognized by divergent horizontal ridges on the hoof wall, known as laminar rings, which can 
represent altered hoof growth subsequent to previous lamellar insult (Fig. 1.1). Clinical findings 
appear to be among the more accurate prognostic indicators in determining outcome in laminitis 
cases 8, with radiologic evidence of distal phalangeal sinking 16,17, higher body weight 17 and more 
severe laminitis (i.e. higher Obel grades) 17 associated with poorer outcomes . 
 
1.1.1 Laminitis epidemiology 
A recent systematic review summarized and critiqued the previously published literature with 
regard to the epidemiology of naturally occurring laminitis 18. The authors reviewed 69 
publications; of these, 10 were considered of sufficient quality to determine prevalence 8,19–25. 
Within these studies, the prevalence varied between 1.5% and 36.5%. More specifically, of these 
studies, only 2 19,26 involved samples of horses from whole populations (in comparison to 




hospital in the United States 19 in comparison to 23.5% amongst pony club horses in Australia 26. 
These differences may be due to geographic and temporal differences, but they are also 
 
FIGURE 1.1. DIVERGENT RINGS VISIBLE ON THE HOOF WALL ARE OFTEN AN INDICATOR OF PREVIOUS LAMINITIS 
 
likely influenced by signalment and management factors, as well as significant case selection and 
categorization differences. Other Australian data has also shown a relatively high incidence 
amongst ponies, in particular 27 with a recent large historical survey in the UK also having a higher 
prevalence in ponies 28. In a study of a large UK farm of 1000 horses, 23.5% had at least one 
episode of laminitis when followed over six years 22. In that paper, the overall incidence per year 
varied between 7.9% and 17.1%. There are some papers describing much lower frequencies, with 




of 446 ponies (presumed at increased risk of laminitis in comparison to other breeds) 29, the 
cumulative incidences in years one, two and three were 4%, 6.7%, and 9.9%, respectively.  
 
In some studies, laminitis has occurred most commonly in autumn 30,31. Another recent abstract 
from Australia found an increased incidence in spring 32, while a large retrospective study in the 
UK found a peak in May (northern hemisphere summer) 22 and a prospective cohort study in the 
UK finding a peak in summer 14. A large survey in the United States also reported that laminitis 
was a significant cause of foot pain during spring and summer 9. Interestingly, in a large 
retrospective survey from first opinion practices in the UK, the median duration between 
recurrence was approximately one year 28, suggesting a seasonal effect.  
 
Recurrence rates for laminitis are often considered high, although rates appear to vary 
significantly between locations, probably reflecting differences in study methodology as much as 
population differences. An Australian survey revealed that almost 9/10 horses with laminitis had 
at least one recurrence within one year 26. More recent Australian surveys have also revealed 
high incidences of recurrence 27,32. In the study involving the large farm in the UK 22, 33.7% of 
horses had repeated episodes of laminitis, with almost one quarter having recurrences within 
the same year. A large historical survey of first opinion practices in the UK found a recurrence 
rate of more than 70% 28, while a similar, but smaller survey demonstrated an approximately 40% 
rate of previous laminitis in cases identified 17. 
 
Another key factor in the assessment of the epidemiology of laminitis is the reliance on initial 
owner recognition. This may be considered poor, with some suggesting an under-recognition of 
foot pain as laminitis 33 and a recent survey supporting this possibility 34, while pathologic studies 
of naturally occurring laminitis have found evidence of prior episodes of subclinical laminitis in 
these animals 35. In horses and ponies diagnosed with pituitary pars intermedia dysfunction 





1.1.1.1 Risk factors 
Understandably, given that most pasture-associated laminitis is due to underlying endocrine 
disease 30,37, many of the risk factors for laminitis of this nature reflect either PPID, Equine 
Metabolic Syndrome (EMS) or both. Indeed, as expected, PPID and EMS are significant risk 
factors for laminitis 28. 
 
There is evidence for a sex bias in laminitis with females being more likely to suffer from disease 
22,28, although not all studies are in agreement 31,37. In a multicenter, case-control study of over 
250 cases from six teaching hospitals, Alford et al 38 found that in chronic laminitic cases, Quarter 
Horses were more at risk than Thoroughbreds, despite recent literature suggestion that they are 
insulin sensitive, relatively speaking [see section 1.4.6.7 Breed and genetics] 39,40. The same 
survey 38 did not test for insulin dysregulation (ID), however. In a survey of laminitic horses and 
ponies presented to a veterinary hospital, older age and pony breeds were associated with 
laminitis 37. Age has been identified as a risk factor elsewhere 9,31,38,41, as has pony status 27. There 
is conflicting data on whether the risk of laminitis continues to increase with increasing age, with 
some literature supportive of this 31, and some suggesting that while middle-age and geriatric 
horses have an increased odds of laminitis in comparison to young horses, they have similar odds 
to each other 38. Several risk factors from Carter et al 41 are described in Table 1.1. 
 
Obesity has been identified as a risk factor for laminitis 24,41–43, probably because of its association 
with ID. Similarly, a cresty neck has also been associated with laminitis 38,42. One study has shown 
that diet (low vs high NSC content) was not a risk factor for either current or historical laminitis 
44. This is partially supported by Potter et al 27, who found that energy-supplying supplementary 
feed was not associated with laminitis, although access to pasture was. This is in contrast to other 
literature 9,45 and expert consensus. Weather may play a role in the incidence of laminitis 22, likely 
through its effects on the NSC concentrations of feedstuffs. 
 
Insulin dysregulation is associated with laminitis  42, given the potential causal link. In a 




 Cut-off Sensitivity, 
% 
Specificity, % IROC LR+ LR- 









 Insulin (µU/mL) >32 100 (61-
100) 








RISQI (µU/mL-0.5) <0.17 100 (61-
100) 



































Body condition score ≥7 100 (61-
100) 








Girth:height >1.3 100 (61-
100) 
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TABLE 1.1. DIAGNOSTIC STATISTICS FOR THE PREDICTION OF LAMINITIS IN PONIES USING A DEFINED CUT-OFF VALUE 
FOR EACH VARIABLE ARE SENSITIVITY, SPECIFICITY, AREA UNDER THE LOCAL RECEIVER OPERATOR CHARACTERISTIC CURVE 
(IROC), AND LOG LIKELIHOOD RATIOS FOR THE POSITIVE (LR+) AND NEGATIVE (LR-) TESTS. VALUES IN PARENTHESES 





insulin, insulin post-dexamethasone and IGF-1 concentrations and decreased adiponectin 
concentrations were risk factors for laminitis after multivariate logistic regression for all years  29. 
Understandably, collinearity existed between basal and post-dexamethasone insulin 
concentrations in that study. Initial basal insulin concentrations were also associated with future 
laminitis in a prospective cohort study 24, as were the subsequent proxy derivatives. Similarly, 
leptin concentrations have been used to identify ponies that go on to develop laminitis 42. 
 
Risk factors also appear to vary between first and subsequent laminitis episodes. In a large 
retrospective study of first opinion practices in the UK, prednisolone was associated with 
recurrence, but not the initial episode 28. Another study 43 has shown that corticosteroids within 
the previous 30 days are a risk factor, however. Furthermore, risk factors for critical illness-
associated laminitis are quite different to those of pasture-associated or endocrine-mediated 
laminitis 11. 
 
In summary, increasing age is a consistent risk factor among studies, as has been confirmed by a 
recent systematic review 46, while other factors appear to vary between populations. Perhaps 
presciently, several scientists correctly identified insulin resistance as being a risk factor for 
laminitis more than 25 years ago 47. 
 
1.1.2 Laminitis aetiology 
1.1.2.1 Gastrointestinal carbohydrate overload 
Previous theories of pasture-related laminitis involved carbohydrate (CHO) overload and caecal 
dysfunction as a potential aetiology. Oligofructose and enteral starches can reliably induce 
laminitis in less than 48 hours, as reflected in previous experimental models 48–50. The hypothesis 
in these cases involved an initial osmotic effect followed by luminal acidosis and thus altered 
hindgut microbiota 51,52 leading to absorption of endotoxin 50. This endotoxin absorption was 
suspected of leading to altered laminar perfusion, basement membrane dysadhesion and thus 





However, this is no longer thought to be a plausible mechanism for several reasons. The 
histopathology of CHO-induced laminitis 49 is different to naturally occurring or 
hyperinsulinaemia-induced experimental 54,55 laminitis  [see section 1.2.4 Histopathologic 
evidence for hyperinsulinaemia]. In addition, most horses administered acute overloads of 
oligofructose developed acute colitis, with several horses dying 48, which is not typically seen with 
pasture-associated laminitis. Although horses and ponies can theoretically ingest enough NSCs 
from pasture as can induce caecal dysfunction experimentally 45, in a pasture setting ingestion 
typically occurs over many hours 48, rather than as a bolus. Furthermore, when fructans are fed 
on a meal basis, increased vasoactive amines were detected within the large colon, but not the 
bloodstream 56, suggesting that normal meal feeding of fructans may not be comparable to acute 
nasogastric intubation with high doses. Thus, the acute ingestion of a quantity of NSCs sufficient 
to cause caecal dysfunction is an unlikely cause of chronic, pasture-associated laminitis. 
Interestingly, the OF experimental model does not result in changes in IS despite the induction 
of laminitis 57. 
 
1.1.2.2 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs) have been implicated in the development of laminitis in a 
variety of experimental settings 53. In the hyperinsulinaemia model of laminitis, MMP-9 gene 
expression and concentrations have been shown to be increased 58. Conversely, in the same 
study, MMP-2 has been shown not to be increased. Goetzl et al 59 showed that MMP-9 is primarily 
derived from leukocytes, and so a pro-inflammatory state might increase the expression of this 
enzyme. While a pro-inflammatory state has been shown to exist in naturally occurring ID [see 
section 1.4.4 Systemic inflammation], MMP activation was not thought to be a factor in the 
hyperinsulinaemia experimental model 58. The authors hypothesized that insulin may be directly 
pro-inflammatory in this regard. 
 
1.1.2.3 Reduction/oxidation 
The current evidence does not suggest a significant role for reactive oxygen species in the 






The current evidence does not suggest that hyperthermia alone plays a significant role in the 
development of experimentally-induced laminitis 61. However, it may be a component of insulin-
mediated disease 42,62. 
 
1.1.2.5 Endocrine disease 
In more recent years, the most commonly identified cause of laminitis in most populations is 
endocrine disease, specifically PPID 30,37 or EMS 37. Several studies have shown that the 
prevalence of PPID in hospitalized laminitis cases can be as high as 70% 30. One study showed 
that endocrine causes account for 90% of laminitis admissions 37. However, that study used 
relatively insensitive diagnostic methodologies (basal insulin and hypertrichosis) for disease 
diagnosis, suggesting that the prevalence may actually be higher. Other studies of PPID horses 
have shown that the prevalence of laminitis within those horses can range from 13-84% 63–66, 
with the prevalence being higher than in control horses 66. In one study that evaluated horses 
with at least one potential clinical sign of PPID, 61.7% had an endocrinopathy 67. While there was 
obvious self-selection of cases, it should be noted even with relatively sensitive inclusion criteria 







1.2 Insulin Dysregulation 
Insulin dysregulation (ID) is defined as any combination of cellular insulin resistance, fasting 
hyperinsulinaemia, excessive post-prandial hyperinsulinaemia or delayed insulin clearance 33,68. 
Delayed insulin clearance may play a role in the development of ID in horses as demonstrated by 
increased C-peptide (cleaved from proinsulin to form insulin) concentrations post-dextrose in the 
insulin-modified, frequently sampled IV glucose tolerance test (FSIGTT) 69. This study was 
performed in relatively insulin-sensitive, non-obese horses, however, and results should be 
replicated in ID horses before the role of delayed insulin clearance can be completely defined. In 
addition, the authors point out that they assume that C-peptide clearance is unaffected by insulin 
dysregulation. Cellular insulin resistance and hyperinsulinaemia are discussed further below. 
 
1.2.1 Development of hyperinsulinaemia and insulin resistance 
Insulin resistance (IR) may lead to hyperinsulinaemia as a compensatory mechanism to maintain 
normal blood glucose concentrations in the face of decreased peripheral utilization, potentially 
in a self-perpetuating cycle (so called homologous desensitization) 33,69–76. Cellular IR leads to 
pancreatic beta cell stimulation and thus increased insulin secretion. In horses specifically, IR 
leads to decreased GLUT-4 expression in equine skeletal muscle 76; since this is a major route of 
intracellular glucose transport, a reduction in GLUT-4 expression may lead to glucose-mediated 
hyperinsulinaemia as compensation. 
 
Hyperinsulinaemia has also been hypothesized as being a precursor to cellular IR 33,77–80. This 
might occur through receptor downregulation or other mechanisms, although the research on 
receptor downregulation is conflicting. One study in obese ponies found that an increased 
number of digital microvascular endothelial cells expressed insulin receptors despite being in a 
hyperinsulinaemic state 81. Furthermore, when insulin infusions were administered for 48 hours 
to induce laminitis in healthy Standardbreds 82, no reductions in skeletal muscle GLUT-4 
expression were identified, making insulin-dependent receptor downregulation less likely. There 
are data supporting the role of insulin receptor downregulation, however 83. In a study of mares 




higher NSCs) demonstrated down-regulation of insulin receptor gene expression in subcutaneous 
adipose tissue 84, although none of these mares was classed as IR by an FSIGTT. Another study 
involving hyperinsulinaemia as part of a hyperinsulinaemic euglycaemic clamp test (HEC) used 
to induce laminitis confirmed reduced expression of insulin receptors in lamellar tissue 85. It has 
also been shown that not all ponies that have excessive insulin responses to oral glucose have 
abnormal combined glucose-insulin tolerance tests (CGIT; and  
 
 
FIGURE 1.2. THE CAUSE AND EFFECT RELATIONSHIP BETWEEN INSULIN RESISTANCE AND HYPERINSULINAEMIA 




thus cellular IR) 77. Other work has demonstrated that hyperinsulinaemia may lead to IR through 
alternative mechanisms such as alteration in expression of a mitochondrial uncoupling protein 
87, or through maintenance of the so-called disposition index 88. 
 
Regardless of which is the initiating factor, there is a close relationship between excessive post-
prandial hyperinsulinaemia and insulin sensitivity. One study comparing a modified oral sugar 
test (OST) and the HEC found that the β-cell responsiveness demonstrated by the OST was 
inversely proportional to the insulin sensitivity in a hyperbolic manner 88. Thus, the 
hyperinsulinaemic response to oral sugar depends on the degree of IR present.   
 
1.2.2 Insulin dysregulation and laminitis 
There is a reproducible association between hyperinsulinaemia and the presence or subsequent 
development of laminitis 24,29,42. Ponies with a previous history of laminitis have been shown to 
be less insulin sensitive than non-laminitic ponies as measured by the FSIGTT 75. In one 
experimental study, peak insulin concentrations were associated with the onset of laminitis when 
ID has been induced with high NSC diets 73, while another demonstrated clinical cases of laminitis 
in horses fed high NSC diets that had higher insulin concentrations 89. There may also be a dose-
response effect of insulin on both the risk of laminitis, as well as the degree of histopathologic 
change, with insulin concentrations of approximately 200 µU/mL being associated with a high 
risk of impending subclinical or clinical laminitis, depending on the timeframe 32,90,91. A survey 
performed in the United States has shown that higher Obel grades of laminitis are associated 
with higher basal insulin concentrations 92. A preliminary survey in Australia had similar findings 
32, although these data have been presented in abstract form only. Ponies that have had previous 
episodes of laminitis have also been shown to be more insulin dysregulated than those not 
thought to be at risk 75. The numbers in this study were small, and the ponies were all obese. 
They were well matched with controls, however. Insulin concentrations have also been shown to 
be associated with mortality in laminitis. In a study of 20 horses with PPID 93, there was a 90% 
chance that a horse did not survive when the insulin concentration was ≥188.6 μU/mL, while a 




laminitic ponies had strict dietary management to prevent recurrence, their basal insulin 
concentrations were not significantly different from normal ponies 94. 
 
In a landmark paper in the current understanding of the pathophysiology of endocrine-associated 
laminitis, induced hyperinsulinaemia (via the HEC) reliably lead to laminitis in ponies without a 
history of laminitis 95. That group used moderately overweight ponies with normal basal insulin 
concentrations fed lucerne hay (i.e. relatively low in NSC concentration). Laminitis was reliably 
induced within 36 hours of hyperinsulinaemia but not in control horses. The hypothesis that 
prolonged, marked hyperinsulinaemia could cause laminitis was reinforced when the experiment 
was repeated using healthy Standardbreds 62, a breed thought of as being insulin sensitive 96,97 
and thus at low risk of endocrinopathic laminitis. In that study, all treated horses developed 
histologic evidence of laminitis while none of the control horses did 62. More recently, laminitis 
(albeit subclinical) has been induced at much lower concentrations of insulin (approx. 200 μU/mL 
98 vs >1000 μU/mL in the original papers 62,95). The duration of hyperinsulinaemia seems to be 
important in the induction of laminitis as well as the peak concentrations 99. The peak insulin 
doses in a study where insulin was administered to assess the response to glucose in light breed 
horses 100 was much higher than that used to induce laminitis in either ponies 95 or Standardbred 
horses 62. Insulin concentrations greater than 800 μU/mL did not lead to significant 
histopathologic evidence of laminitis after 24 hours 101, whereas the majority of animals had 
evidence of laminitis when a similar experiment was continued for 48 hours 62. In a study that 
induced marked hyperinsulinaemia but only for six hours, no laminitis was reported, although 
this was not a defined endpoint of the study 79. Bamford et al. 102 suggested that once daily high 
NSC meals may not have led to sufficient downregulation of insulin receptors to IR. Indeed, 
multiple daily episodes of hyperinsulinaemia may be necessary for IR to develop due to chronic 





1.2.3 How insulin dysregulation might cause laminitis 
1.2.3.1 Hyperglycaemia 
Laminitis has been induced by prolonged hyperinsulinaemia as part of a euglycaemic clamp 
procedure 62,95. In both studies, euglycaemia was maintained. However, by definition, larger 
absolute quantities of glucose were delivered to the lamellae. Further research by the same 
group has shown that infusion of the same supraphysiologic quantities of glucose leads to similar 
hyperinsulinaemia and subsequently laminitis, albeit subclinically 90. These two studies suggest 
that while hyperglycaemia may lead to laminitis, it is probably mediated through 
hyperinsulinaemia, with direct glucotoxicity less likely. In naturally occurring laminitis, 
hyperglycaemia is uncommon 70,92, further supporting this assertion. While laminitic Andalusians 
were found to have elevated glucose concentrations relative to healthy controls 103, the 
concentrations were not statistically different and the laminitic horses were tested within 24 
hours of onset of laminitis. Thus, the elevations may relate more to an acute stress response than 
underlying insulin dysregulation.  
 
1.2.3.2 Insulin resistance 
Cellular IR as a cause of lamellar failure is also not supported by the literature. The lamellae have 
been found to have very high glucose requirements 104, even exceeding that of the head at rest 
105. Furthermore, digital lamellae kept in tissue baths without glucose quickly results in laminar 
separation while the addition of glucose prevents separation for 8 days 106. Insulin-mediated 
glucose uptake, through GLUT-4 receptors, is the major mechanism for skeletal muscle uptake of 
glucose 82. The digital lamellae, however, have been shown to have minimal or no expression of 
glucose transporter (GLUT)-4, as demonstrated by mRNA expression by PCR 104 and 
immunoblotting 82. Additionally, the digital lamellae do not express insulin receptors, as 
demonstrated by immunoblotting 81. The microvascular endothelium, however, do express 
insulin receptors, as demonstrated by the same study 81. These receptors have been shown to be 
increased in association with increased NSC diets 81. Finally, insulin administration did not 
increase the glucose uptake of the digital lamellae over basal in hyperinsulinaemic ponies 104, nor 




82. Instead, the lamellae are probably supplied with their glucose requirements through glucose-
mediated glucose uptake through GLUT-1 receptors 82,104, independently of insulin. Interestingly, 
one study found that GLUT-8 and -12 were expressed in different quantities between control 
horses and horses treated with insulin infusions 82 although the significance of this is unknown. 
Thus, the causative role of hyperinsulinaemia in laminitis may be a direct effect of insulin itself. 
 
1.2.3.3 Hyperinsulinaemia 
Hyperinsulinaemia may lead to laminitis through several potential mechanisms. As previously 
mentioned, it has been shown that insulin receptors within the foot are found exclusively on the 
microvascular endothelium; there are no identifiable receptors on the laminar epithelium 81. 
Thus, the role of insulin may relate to its vasoactive effects. In further support of the vasodilator 
roll increased insulin concentrations may play in the normal horse, increased blood flow to the 
foot has been linked to increased insulin concentrations after meals 107. That group suggested 
that the increased flow may relate to insulin-mediated endothelial-derived nitric oxide (NO) 
release 107. In an experimental model of laminitis, horses that were treated with prolonged insulin 
infusions had higher hoof wall temperatures in comparison to control horses 62. The authors 
postulated that this increased hoof wall temperature may be associated with insulin-mediated 
vasodilation 62. In humans, the evidence is somewhat contrary to this hypothesis (increased 
vasodilation in hyperinsulinaemic states). It has been shown that cellular insulin resistance 
differentially affects the phosphoinositide (PI3) kinase– and mitogen-activated protein (MAP) 
kinase–mediated signaling systems in the vasculature within human muscle. In obese humans, 
PI3 kinase (responsible for NO mediated vasodilation) was markedly reduced and absent in 
people with T2DM 108. In contrast, insulin-mediated stimulation of MAP-kinase (which leads to 
endothelin-mediated vasoconstriction) was found to be normal in these humans 108. It has been 
shown that MAP kinase activation occurs in laminar tissue in the CHO model of laminitis 109, 
although this has not been reported in insulin-mediated laminitis. Horses may also undergo 
reduced insulin-associated, NO-mediated vasodilation in hyperinsulinaemic laminitis 62, although 
the data is incomplete in this area. Pre-existing hyperinsulinaemia has been shown to alter the 




80. Alternatively, low adiponectin concentrations may lead to decreased vasorelaxation of the 
equine digital vasculature 29. Morgan et al 110 has also shown a reduction in endothelium-
dependent vasodilation in laminar vessels in obese, hyperinsulinaemic laminitic horses, albeit in 
small numbers. Thus, ID may lead to an imbalance between vasoconstrictive and vasodilatory 
mediators (Fig. 1.3). These vasoactive mediators are not detectable in peripheral blood after 
insulin infusions 111, and may only be active in significant quantities in local tissue beds, such as 
the lamellae.  
 
 
FIGURE 1.3. THEORETICAL RELATIONSHIPS BETWEEN INSULIN SENSITIVITY AND VASCULAR TONE IN HORSES. 
ALTERATIONS IN INSULIN SENSITIVITY MAY DETERMINE WHICH PATHWAY PREDOMINATES AFTER ACTIVATION BY 






An alternative hypothesis involves insulin-like growth factor (IGF)-1 receptor activation. At 
supraphysiologic concentrations, insulin has been shown to bind and activate IGF-1 receptors in 
other species 113. Concentrations of IGF-1 have been shown to be increased in horses fed high 
NSC diets 74 and non-specific insulin-binding of IGF-1 receptors may also occur in horses 85,101. A 
trend towards increased IGF-1 concentrations has been detected in obese mares 114. 
Hyperinsulinaemia leads to insulin receptor and IGF-1 receptor downregulation through specific 
and non-specific overstimulation, respectively, without any detectable rise in serum IGF-1 
concentrations 85. This IGF-1 receptor stimulation may lead to lamellar cell proliferation and thus 
lamellar weakening 85. It has been shown that cell proliferation occurs early in the developmental 
phase of experimental insulin-induced laminitis 101. Recent literature has characterized the 
laminar tissue expression of various insulin and IGF receptors 115,116. Those authors suggest that 
during hyperinsulinaemia, insulin may mediate growth, adhesion and survival, rather than 
metabolism. One study also suggested that obesity and high NSC diets both influence expression 
of these receptors, with an inverse relationship between insulin concentrations and receptor 
expression 115. Another group 29 has postulated that combined hyperinsulinaemia and 
hypoadiponectinaemia may lead to altered expression of insulin and IGF-1 receptors in lamellar 
endothelia and epithelia, respectively, based on human data 117. Downstream signaling pathway 
products of IGF-1 receptor stimulation have been identified in the lamellae of obese ponies fed 
high NSC diets for seven days, with modest correlations with insulin concentrations observed 118. 
That study also identified increases in phosphorylated IGF-1 signaling pathway products in 
Standardbreds that had hyperinsulinaemia-induced laminitis. A recent study has shown that 
insulin does not bind to IGF-1 receptors at physiologic (or even pathophysiologic) concentrations 
116, however, complicating the current understanding of the role of insulin activation of IGF-1 
receptors in the digit. 
 
1.2.4 Histopathologic evidence for hyperinsulinaemia-induced lamellar lesions  
In the original paper describing hyperinsulinaemic laminitis 95, histopathology of the affected feet 
revealed that the tips of the secondary epidermal lamellae (SEL) were elongated and tapered, 




similar to pathologic findings in both experimental hyperinsulinaemic laminitis in Standardbreds 
55 and naturally occurring, ID-associated laminitis 35 and PPID-associated laminitis 119. It does not 
completely agree with histopathologic findings in a CHO-overload model of laminitis, which tends 
to have more severe BM disruption 49. Experimentally, in general, there is SEL lengthening in both 
models of laminitis 55, although there was less evidence of inflammation in the hyperinsulinaemia 
model of laminitis 54,55. Recent research has also shown that lamellar explants weaken in the 
presence of insulin 120. There appears to be a difference with regard to BM disruption between 
horses 55 and ponies 54; this has been postulated to be due to differences in bodyweight 55. 
Laminitis occurring secondary to the experimental chronic feeding of high-NSC diets does not 
lead to leukocyte infiltration or increased inflammatory markers within laminar tissue 121, again 
in contrast to the CHO model of laminitis 122. Furthermore, MMP activity in the lamellae in 
hyperinsulinaemia-induced laminitis is much lower than that in CHO-induced laminitis 58. 
 
1.2.5 Insulin dysregulation in EMS 
1.2.5.1 Incretins 
There are three currently identified incretins – glucagon-like peptides 1 and 2 (GLP-1, 2) and 
glucose-dependent insulinotropic peptide (GIP) - which are secreted from L and K cells of the 
small intestine, respectively 123. These hormones are released in response to intestinal amino 
acids, glucose and fats 123. In humans, incretins have been found to be significant insulin 
secretagogues 123 and this has recently been confirmed in horses in vitro 124,125. Assays for the 
assessment of GLP-1, GLP-2 and GIP have been validated for use in horses 77. The gastrointestinal 
stimulus for insulin secretion, mediated by these incretin hormones, is referred to as the 
enteroinsular axis 77. 
 
The contribution of incretins to the induction of hyperinsulinaemia in horses has been evaluated, 
albeit incompletely thus far. There appears to be a breed difference in incretin response to NSCs, 
with ponies and Andalusians having higher GLP-1 responses post-prandially than Standardbreds 
96. Earlier research found no difference between horses and Shetland ponies, however 126. A 




concentrations associated with higher body condition and cresty neck scores 124. Interestingly, a 
recent study has shown no difference in GLP-1 responses in insulin sensitive or resistant horses 
using the OST 89, although the latter has a much lower sugar dose than the IFGT. In addition, that 
study demonstrated wide interindividual variability in GLP-1 concentrations. When the incretin 
response to oral carbohydrates was assessed using the IFGT, the responses were lower than 
reported in other species 77, suggesting that glucose is the major determinant of pancreatic 
release of insulin in horses. When the in vitro pancreatic response to GIP and GLP-1 antagonists 
was investigated, a reduction in insulin release of 30% 124 and 27% 125 was found, respectively. 
While the relatively low level of antagonism may be related to various confounding factors, the 
role of incretins may not be as important in equids in the development of post-prandial 
hyperinsulinaemia, in comparison to other species, at least with regards to direct effects. A recent 
paper has demonstrated increased GLP-2 concentrations in ponies with ID 127. This incretin is 
thought to be intestinotropic in other species, and may explain why glucose bioavailability is 
increased in ponies with ID. 
 
1.2.5.2 Genetics 
An alternative, or perhaps complementary, hypothesis relates to a potential genetic 
predisposition. Initial reports suggest an association with a gene involved with cholesterol 
metabolism 128 [see section 1.4.6.7 Breed and genetics].  
 
1.2.6 Insulin dysregulation in PPID  
Insulin dysregulation has long been associated with PPID 66,129,130. It has recently been reported 
that between 30 and 60% of horses with PPID will have concurrent ID 36. Horses with PPID were 
more likely to have IR than clinically normal horses in one study 129. However, age was a potential 
confounder in that study as ID has been shown to be more common in older horses 131,132. 
Similarly, horses with ID were more likely to have PPID than animals with normal insulin statuses 
67. Karikoski et al 37 showed that the majority of PPID horses are insulin dysregulated in a case-





Horses with PPID have been shown to have higher basal insulin concentrations in comparison to 
normal horses 129,133,134 or horses with pasture-associated laminitis 32. They have also been shown 
to have reduced insulin sensitivity as assessed by the HEC 135. Furthermore, Frank et al 136 showed 
that horses with PPID had elevations in insulin concentrations in autumn in comparison to spring, 
despite similar pasture ethanol-soluble CHO content. Basal hyperinsulinaemia has previously 
been found to be a sensitive indicator of PPID in horses selected with specific testing 
(histopathology and hypertrichosis) 134. 
 
Horses with both PPID and EMS have also been reported to have higher insulin concentrations 
than those with either condition alone 32. Furthermore, EMS and PPID horses had similar insulin 
concentration that were higher than control horses under similar management in a longitudinal, 
clinical survey 92. Interestingly, it may be that horses with PPID and ID concurrently are likely to 
get laminitis, whereas those with PPID but not ID, are not 66,119. It has also been found that PPID 
horses that have laminitis are more likely to have a higher body condition score (BCS) 119, 
presumably related to metabolic derangements and concurrent ID.  
 
There is also some evidence suggesting that ID might progress with progression of PPID. Keen et 
al 137 found that horses with PPID as diagnosed by hypertrichosis (considered an advanced clinical 
sign) had significantly higher insulin concentrations in comparison to horses with positive 
dexamethasone suppression test (DST) but no hypertrichosis. This suggests that upregulation of 
the hypothalamic-pituitary-adrenal (HPA) axis might accentuate insulin dysregulation. 
 
It may be that PPID modifies or accentuates the genetic predisposition to hyperinsulinaemia. 
However, it has also been found that corticotropin-like intermediate lobe peptide (CLIP) acts as 
an insulin secretagogue in other species 138 and thus may contribute to hyperinsulinaemia in 
PPID. Another hypothesis is based on the finding of increased free cortisol in association with 
hyperinsulinaemia 139. That group hypothesized that increased 11-beta-hydroxysteroid 




hyperinsulinaemia through hepatic gluconeogenesis and failure of GLUT-4 membrane 
localization. 
 
There is other data that has shown no effect of PPID on OST results 140. Additionally, in an age-
matched study between PPID and control animals using an isoglycaemic hyperinsulinaemic 
clamp, no differences were identified between groups 141. It may be that certain populations of 
PPID horses are likely to be insulin dysregulated, independent of other factors. However, a 
limitation of that study 141 is that the reporting of DST and adrenocorticotropic hormone (ACTH) 
results in control horses is incomplete, making generalizability difficult. 
 
As previously mentioned, ID has been associated with prognosis in PPID horses. In a longitudinal 
study of 20 PPID horses, there was a 90% chance that a horse would not survive when insulin 
concentrations were greater than or equal to 188.6 μU/mL, while those horses with an insulin 
concentration of less than or equal to 61.4 μU/mL had a 90% chance of survival 93. The presence 
of more severe ID in PPID-affected animals has also been associated with worse radiographic 
changes and greater owner recognition of laminitis 36, 
 
There is also a report of pergolide treatment in a horse with minimal model-confirmed type two 
diabetes mellitus, and concurrent PPID, resulting in lower insulin concentrations after an initial 
increase, with no other management changes 142. In certain circumstances, ACTH concentrations 
have been negatively associated with the presence of laminitis 42. It is unclear if animals with 
PPID were being treated in that study, although the effects on diagnosis of laminitis (i.e. the 






1.3 Pituitary Pars Intermedia Dysfunction 
Pituitary pars intermedia dysfunction is a neurodegenerative condition of usually older horses 
that occurs worldwide 4. The condition is thought to represent the loss of inhibitory signaling to 
the melanotropes of the pars intermedia of the pituitary gland 143. This is thought to be due to 
neurodegeneration of dopaminergic hypothalamic neurons that exert an inhibitory signal on 
melanotropes 144. This neurodegeneration is thought most likely due to oxidative damage 145,146, 
although this is not confirmed. The pars intermedia melanotropes undergo hyperplasia, leading 
to micro- and subsequently macroadenoma development 147 and altered (usually upregulated) 
pro-opiomelanocortin (POMC) expression 148. It has been shown that circulating concentrations 
of POMC itself do not increase in PPID, despite increases in pituitary expression, suggesting post-
translational or secretory factors play a role in the pathophysiology of the disease 148. These 
factors result in increased circulating concentrations of POMC-derivatives, such as ACTH and 
alpha-melanocyte-stimulating hormone (α-MSH), however 148. The altered expression of POMC-
derivatives is thought to be responsible for the generation of clinical signs 147, which include 
laminitis, hypertrichosis (formerly and erroneously hirsutism), weight loss, polyuria/polydipsia 
and immunosuppression 4. 
 
1.3.1 Epidemiology of PPID 
In one hospital in the Netherlands in the early 1990s, PPID accounted for up to 0. 5% of hospital 
admissions 130. This may represent selection bias due to the referral nature of the practice, 
however. In an international survey of practitioners, an overall estimated prevalence of 1% was 
reported, that did not appear to differ based on location 149. In another study, the proportional 
representation over time increased from 0.25/1000 to 3.72/1000 over a 10 year period 63. 
Whether this relates to increased horse longevity, better diagnostic testing or a true increase in 
the prevalence of disease is unknown. Amongst the general population, one study in Queensland, 
Australia, demonstrated a prevalence of PPID of 21.2% in horses over 15 years of age, based on 
ACTH concentrations above seasonal cut-off values 66 while others demonstrated hair coat 
changes suggestive of PPID in 22% of horses older than 15 years 150, rising to 39% of horses older 






As stated above the prevalence of PPID increases with age 66. In fact, age is a strong independent 
predictor of PPID status with horses between 15 and 19.9 years of age being 2.2 times more likely 
of having PPID in comparison to horses <15 years of age 67. This rises to 4.6 times for horses 
between 20 and 24.9 years of age and 14 times for horses >25 years of age 67.  
The disease has no apparent sex predilection 4, although this has recently been challenged based 
on resting ACTH concentrations 151. Ponies may be more likely to have PPID than horses 4,64,151,152, 
although this is refuted elsewhere 66. Signalment as described by Ireland and McGowan 153 is 
described in Table 1.2. 
 
1.3.3 Clinical Signs 
Hypertrichosis, previously erroneously called hirsutism, is considered a specific clinical sign of 
PPID, with a reported positive predictive value of 91% 154. However, given the association 
between PPID and laminitis, it seems prudent to diagnose PPID before hypertrichosis develops, 
given its appearance potentially later in disease than laminitis 30,155. Weight loss is also associated 
with PPID 156 while other clinical signs (such as muscle atrophy lethargy, polyuria and polydipsia, 
and recurrent or unusual infections) are considered non-specific 66, but may be overlooked in the 
early stages of disease. There may also be an infrequent association with suspensory ligament 
desmitis 157. Various diagnostics have been evaluated for PPID and most have inadequate 
sensitivity, specificity or reproducibility. These include basal cortisol 130, the domperidone 
stimulation test 158, loss of diurnal cortisol rhythm 159, the cortisol response to thyrotropin-
releasing hormone (TRH) administration 160, the cortisol response to ACTH administration 64,161, 
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TABLE 1.2. CHARACTERISTICS OF 385 HORSES AND PONIES WITH CLINICAL SIGNS OR CLINICOPATHOLOGIC DIAGNOSIS OF PPID (MODIFIED FROM IRELAND AND 







Histopathology is traditionally thought of as the ‘gold-standard’ diagnostic for PPID 161,169. The 
pituitary changes are graded out of 5, where 1 is within normal limits (Fig. 1.4) and 5 is a 
macroadenoma (Fig. 1.5) 170. However, there are several problems with histopathology being a 
valid ‘gold-standard’. One study has shown that there are histologic changes in the pituitary gland 
associated with season 169. In this study, grade 4/5 changes (microadenomas) were detected in 
autumn in horses euthanized for diseases not consistent with PPID. These findings might 
represent false positives in animals with a low pre-test probability in autumn 169. Interestingly, in 
that study, the pars distalis and pars nervosa histometry findings did not change during autumn. 
Depending on the time of year, grade 4/5 changes may or may not represent disease. Another 
study found grade 3/5 (diffuse hyperplasia) and 4/5 changes in the pars intermedia of clinically 
normal mares at various times of the reproductive cycle 171, indicating that this may also affect 
pituitary gland histopathology. Other factors which may affect pituitary histometry and histology 
have not been elucidated.  
 
Another potential problem with using histopathology is that agreement between pathologists 
might vary. One study found that in cases with strong supporting (clinicopathologic) evidence of 
disease, there was very good to excellent agreement between pathologists 172. That study also 
demonstrated good agreement in cases unlikely to be diseased. The difficult appears to lie in 
cases where the clinicopathologic diagnosis is unclear 172, where a ‘gold standard’ test might be 
needed to better stratify diseased and healthy animals. While a more recent study found better 
(but not perfect) agreement 169, there are concerns associated with using histopathology as 
validation of other diagnostic tests. Finally, horses with pituitary microadenomas 170,171 or 






FIGURE 1.4. MEDIAN SAGITTAL SECTION OF A HAEMATOXYLIN AND EOSIN-STAINED NORMAL EQUINE PITUITARY GLAND. 
THE PARS INTERMEDIA (PI) IS A NARROW BAND OF ENDOCRINE TISSUE LOCATED BETWEEN THE PARS DISTALIS (PD) 
AND PARS NERVOSA (PN). THE PARS TUBERALIS (PT) SURROUNDS THE INFUNDIBULAR STEM (IS; MODIFIED FROM 
MCFARLANE 2014  173).  
 
1.3.4.2 Computed tomography 
There are conflicting reports of computed tomography (CT) being useful in the diagnosis of PPID 
174,175. In the Pease study 175, CT was quite well correlated with necropsy findings (size and volume 
when adjusted for body mass). However, these horses were all quite advanced clinically and were 
all grade 5/5 on PM. The earlier study 174 used older technology, but did not find the modality as 
useful, with large variations between CT and PM measurements. With increasing popularity of 
standing head CT facilities available for horses and improving spatial resolution, CT may become 
an important research tool in the future. The effects of seasonal changes in pituitary size on the 
diagnosis of PPID using CT also needs to be investigated. It is unlikely to become a practical clinical 





FIGURE 1.5. MEDIAN SAGITTAL SECTIONS OF PITUITARY GLANDS FROM HORSES WITH PPID. A) HAEMATOXYLIN AND 
EOSIN-STAINED SECTION OF A PITUITARY GLAND FROM A HORSE WITH MICROADENOMAS OF THE PI. MINIMAL 
COMPRESSION OF THE PARS NERVOSA (PN) AND PARS DISTALIS (PD) IS PRESENT. ARROWS HIGHLIGHT THE 
MICROADENOMAS. B) HAEMATOXYLIN AND EOSIN-STAINED SECTION OF A PITUITARY GLAND FROM A HORSE WITH AN 
ADENOMA OF THE PARS INTERMEDIA. MARKED COMPRESSION OF THE PN AND PD IS PRESENT AND THE GLAND HAS A 
ROUNDED APPEARANCE (MODIFIED FROM MCFARLANE 2014 173). 
 
1.3.4.3 Biomarkers 
Complete blood count and serum biochemical analyses are sometimes abnormal in horses with 
PPID 63. However, the abnormalities seen (mild anemia, neutrophilia,  lymphopenia, increased γ-
glutamyl transferase, creatinine kinase and aspartate aminotransferase activities etc.) are neither 




as a sensitive test for PPID 130; however, this most likely represents those horses that have PPID 
and ID as comorbidities. It likely misses PPID horses with normal insulin responses and is not 
specific for PPID 177. 
 
1.3.4.4 DST 
When first described, the DST was purported to have a sensitivity and specificity of 100% 161. 
More recent evidence has disputed this, however 178, with the original testing likely suffering 
from selection bias involving advanced cases. Durham et al 179 has combined the data from three 
papers 154,161,180 evaluating the diagnostic accuracy of the DST and found an overall test sensitivity 
of 89% and specificity of 88%. Marked discrepancies have been observed between clinical signs, 
ACTH concentrations and results of the DST 137. Indeed, the post-mortem findings in PPID horses 
and those with pituitary hyperplasia were not correlated with the results of the DST 180. In 
another study, a significant portion of normal and laminitic ponies had changing test results over 
time 181, which has also been observed elsewhere 178. In a study using hypertrichosis as the ‘gold-
standard’, the DST was positive in only 50% of horses, whereas endogenous ACTH concentrations 
were abnormal in 92% of horses 137. The time of year of testing was not mentioned in this report, 
however, which may have confounded the results. Part of this poor performance may relate to 
the fact that the melanotropes of the pars intermedia may not express glucocorticoid receptors 
182. Additionally, it has been recommended that the DST not be performed as a PPID diagnostic 
in autumn due to the propensity for false-positives based on current cut-off limits 183. Seasonally-
adjusted cut-off values may overcome some of this poor specificity, but this data is not available. 
 
While not reported 181, some authors have considered the risk of corticosteroid-associated 
laminitis as a drawback for the DST 155. Indeed, the dose of dexamethasone used in the DST has 
been shown to induce temporary insulin resistance 184, which may increase the risk of laminitis 
in association with concurrent high NSC feed. The test also requires two separate venepunctures 
on consecutive days, making the test potentially less practical for clients. Thus, there is a need 
for an accurate, practical ante-mortem diagnostic that removes some of the potential downsides 





1.3.4.5 Alpha-melanocyte stimulating hormone 
Alpha-MSH is thought to be an accurate test for PPID diagnosis, and may be released in higher 
concentrations after TRH-stimulation than ACTH 158. The hormone is typically expressed from the 
melanotropes of the pars intermedia 185,186. Like ACTH, its secretion in normal animals is 
stimulated by arginine vasopressin (AVP) and corticotropin releasing factor (CRF) and 
suppressed by cortisol 187. Alpha-MSH has also been shown to be more stable than ACTH 188. 
However, it is unclear if its accuracy is superior to ACTH’s, with supporting 185 and refuting 189 
evidence in the literature. A major difficulty with the use of α-MSH as a diagnostic tool is the lack 
of a commercially available assay. 
 
1.3.4.6 Adrenocorticotropic hormone 
Adrenocorticotropic hormone was first described as a diagnostic test for PPID in the mid-1990s 
64,130. It is secreted from the pars distalis in normal horses, with peaks occurring between 2 and 
6 times per hour 190–192 when pituitary effluent blood is sampled remotely in unperturbed horses. 
Similarly, when evaluated systemically, adult mares have ultradian rhythms with  peaks occurring 
between approximately 4 and 6 times per hour 192. The release of ACTH in normal horses is closely 
associated with AVP release 190,193,194. During physiologically stressful events, CRF appears to 
modulate this response 195, with the two peptides acting synergistically at lower cortisol 
concentrations 196. Interestingly, in horses perceived as having isolation stress (sweating, 
tachycardia, increased ambulation etc.), those having no significant AVP concentration elevations 
did not have ACTH concentration elevations 194. In normal horses, ACTH is primarily derived from 
corticotropes within the pars distalis (Fig. 1.6) 197,198. In contrast, in PPID, many POMCs are 
derived from the pars intermedia 143,197–199. These POMC products include ACTH, α-MSH, CLIP 
and beta-endorphin, among others 143,147,198. It is thought that the ACTH secreted from the pars 
intermedia in PPID is less likely to be biologically active, which would explain the lack of 
hypercortisolaemia in many animals 180,197. Furthermore, in horses with PPID, ACTH and cortisol 




shown to be genetically homologous to those produced in normal horses 148. Thus, the reasons 
for ACTH inactivity in PPID may relate to post-processing factors. 
 
With regards to the diagnosis of PPID, the sensitivity of plasma ACTH concentration was reported 
in earlier literature to range from 84 to 100% 64,130,200. The specificity reported varied between 
78% using a cut-off of 35 pg/mL and 100% using a cut-off of 50 pg/mL, albeit with different assays 




FIGURE 1.6. POMC PROCESSING PATHWAY. POMC IS PROCESSED DIFFERENTLY IN THE CORTICOTROPES OF THE PARS 
DISTALIS THAN IN THE MELANOTROPES OF THE PARS INTERMEDIA BECAUSE OF THE DIFFERENTIAL EXPRESSION OF THE 
ENZYMES INVOLVED IN THE POSTTRANSLATIONAL PROCESSING STEPS. AC-Α-MSH: ACETYL-ALPHA-MSH; AC-Β-





summer and winter solstices; see section 1.3.4.6.1.4 Circannual rhythm] are reported as being 
100% and 95%, respectively 189. 
 
Discordance has been found between the results of DST, endogenous ACTH concentrations and 
clinical signs in some horses 137, although generally ACTH concentrations correlate well with 
histopathologic findings 170. 
 
1.3.4.6.1 Influences on ACTH concentrations 
1.3.4.6.1.1 Sex 
No association with sex was found when ACTH was measured on several occasions in a group of 
ponies and horses 183. 
 
1.3.4.6.1.2 Age 
Several studies have demonstrated an effect of age on ACTH 180,183,202,203. The cause of this is 
unknown but in some cases may include horses with subclinical PPID 180. The effect is generally 
thought to be weak, however 183 and in one study, no horse was classified as having PPID despite 
increasing ACTH concentrations with age 204. In the Donaldson et al 183 paper, some of the ACTH 
concentrations of animals in autumn are suggestive of subclinical PPID and may represent 
improper categorisation. Other studies have not found an association with age 64,205,206. Thus, 




Some studies have found, when controlled for time of year, that there is no difference between 
horses and ponies with regard to ACTH concentrations 66,183.  Other research has shown that 
normal ponies may have lower 64 or higher 151 concentrations. The latter study did not 
discriminate between PPID-affected and normal animals, however. As ponies have been shown 
to have a higher prevalence of PPID 26, this may confound the breed-effect on ACTH 





1.3.4.6.1.4 Circannual rhythm 
Possibly the most clinically relevant modifier of ACTH concentrations is that related to time of 
year. Indeed, a circannual rhythm of ACTH has long been identified 136,180,183,203,207,208. More 
recent research has identified that the increase in ACTH tends to occur around the time of the 
summer solstice, peaks at the autumn equinox and falls again thereafter 133,209,210 [hitherto 
defined as the dynamic phase of the circannual ACTH cycle 210]. While the mechanism of this 
change is unknown, it seems related to the negative change in daylight hours, rather than actual 
hours, per se 133,209. During this time of year, basal ACTH concentrations in PPID horses are 
actually more separated from normal horses than at other times of the year 211. As such, the 
diagnostic accuracy of the test improves, with sensitivity and specificity reported as being 100% 
and 95%, respectively 189. Conversely, a relatively quiescent phase is apparent when endogenous 
ACTH concentrations are lower and display reduced variability compared to the rest of the year, 
and occurs between the winter and summer solstices 179,210. It should be noted, that there may 
exist a ‘grey zone’ where the basal ACTH concentrations of early PPID and normal horses may 
overlap 179,211,212.  
 
1.3.4.6.1.5 Location 
Several studies have demonstrated effects of latitude on ACTH concentrations, particularly when 
taking seasonal changes into account 185,189,211,213. In general, these studies have shown that ACTH 
concentrations during the quiescent phase of the circannual ACTH cycle are similar regardless of 
location. However, during the dynamic phase, the mean ACTH concentrations tend towards 
higher levels in latitudes closer to the equator 185,189,204,210,211, although exceptions have been 
seen 204.  
 
1.3.4.6.1.6 Feeding and diet 
The effects of feeding on ACTH concentrations are controversial. Diez de Castro et al 214 found 
that fasting increased resting ACTH concentrations. However, in that same study, when 




species, feed-associated increases in ACTH concentrations are mediated via alpha-1 adrenergic 
responses, probably from vasoactive intestinal peptide 214. Other studies have found that feeding 
did not result in significant differences between basal ACTH concentrations when performed as 
part of a TRH-stimulation test 215 or as standalone tests 216. Type of baseline diet may also affect 
ACTH concentrations with a starch-rich diet associated with higher resting ACTH concentrations 
in comparison to an isocaloric fiber-rich diet 203. The latter finding has been replicated in a more 
recent study that showed that starch and sugar diets resulted in higher ACTH concentrations 
particularly in aged horses 203. 
 
1.3.4.6.1.7 Exercise 
Intense exercise has been shown to increase ACTH in the short-term 193,217. The physiologic drive 
of this rise in ACTH is unknown. The increase in ACTH concentrations is short-lived 218, however, 
and does not occur with lower intensity exercise 217 .There is evidence that it may be related to 
exercise-induced rises in AVP rather than CRF 193. 
 
1.3.4.6.1.8 Sickness 
Painful and stressful conditions have been shown to increase ACTH concentrations in horses 219. 
This study used a radioimmunoassay (RIA) to determine ACTH concentrations in various 
grouping of horses including laminitis, acute abdominal syndrome and acute or chronic diseases. 
All these groups had statistically significant increases in ACTH concentrations. However, the 
concentrations were within previously published reference intervals using that methodology 220. 
Another study of sick, hospitalized horses demonstrated illness-dependent effects on ACTH 
concentrations 221. In that study, severely ill horses had markedly elevated ACTH concentrations 
on admission (using an RIA as above) while moderately or mildly ill horses had smaller increases 
in ACTH concentrations. These concentrations had significantly reduced by day 6 of 
hospitalization 221. It is unknown what influences these increases in ACTH concentrations, 
although noradrenaline was increased in one study in conjunction with ACTH 219 while some 






Stress has been shown to increase the amplitude of ACTH secretion from the pituitary gland, 
although not the frequency 195. Stress associated with short- 206 and long-distance 222 transport 
can also affect ACTH concentrations. In particular, it has been shown that horses that have less 
experience being transported, and that are less well handled, have higher increases or basal ACTH 
concentrations, respectively 206. It should be noted that while the time of year was not stated, 
the highest ACTH concentration in that study was 26 pg/mL. 
 
Isolation stress, which has a clinically obvious effect, can cause marked increases in ACTH 
secretion from the pituitary gland, although this was only observed when marked AVP release 
was also observed 194. Furthermore, this AVP increase has been seen within the first minute of 
isolation stress 194. 
 
Venepuncture has also been evaluated as a cause of elevated ACTH concentrations in the 
absence of disease 223. This study showed that while ACTH concentrations were elevated in many 
cases after venepuncture, it is unlikely to alter the diagnostic accuracy of the test in most cases 
223. 
 
1.3.4.6.1.10 Multiple samples 
There is controversy about the clinical significance of the ultradian rhythm of ACTH secretion. 
ACTH is released from the pituitary in a pulsatile manner, with approximately 10 peaks detected 
per hour when sampled directly from the pituitary circulation 190. There is research that has 
shown that these pulses are not detected at peripheral blood level, however 191. Researchers in 
the USA noted duplicate samples and samples taken at 5 minute intervals could vary by greater 
than 50 pg/mL in PPID horses, with control horses having generally much lower variability 180. 
Other more recent research found that in most cases, from a clinical point of view, duplicate or 
paired samples are not required in most cases 212,224. Similarly, the clinical relevance of a 




ACTH concentrations between times of day 214 and others finding differences that are unlikely to 
be clinically significant 159,224.  
 
1.3.4.6.1.11 Drugs 
Opioids seem to inhibit ACTH release through a non-CRF factor 225. Inhibition of opioids thus leads 
to increased ACTH concentrations 225. Insulin administration, apart from causing hypoglycaemia, 
leads to increased CRF, ACTH and AVP release, i.e. activation of the HPA axis 226. Interestingly, 
the lower the glucose concentration in that study, the higher the ACTH and cortisol 
concentrations. Dexamethasone has also been shown to decrease endogenous plasma ACTH 
concentrations, probably through a negative feedback approach  227. That group demonstrated 
that ACTH concentrations were suppressed for up to three days after a 10 day course of topical 
dexamethasone.  
 
1.3.4.6.1.12 Unexplained elevations 
There are reports of ACTH concentrations varying markedly in horses with or without PPID 180. 
One study found that basal ACTH concentration can actually vary in some horses by up to 50 
pg/mL 180 - this occurred more commonly in PPID horses than in normal horses. Several other 
papers have also demonstrated occasional, unexpected elevations above previously published 




Recent research has shown that ACTH is stable at room temperature for between three and eight 
hours 64,230,231, but degrades even if refrigerated between eight to 24 hours post-collection 230,231. 
From both of these studies, it appears that in most cases the decrease at 24 hours would not lead 
to erroneous classification. It appears to remain stable when frozen 231. Centrifugation (vs gravity 
separation) and additives do not appear to make a significant short-term difference 230, although 
separation from red blood cells is important after eight hours 231. There may be differences 




studies in humans have also identified that human ACTH plasma concentrations remain stable 
either with or without aprotinin for up to 72 hours when refrigerated 232,233. 
 
1.3.4.6.1.14 Insulin sensitivity 
In contrast to the data on the effect of PPID on ID, there is little data on the effect of ID on ACTH 
concentrations. One study suggested that there was no effect of ID on ACTH concentrations in 
12 mares 229. 
 
1.3.4.6.1.15 Assay 
There are several assays available for the measurement of equine ACTH. There is a CLIAa that is 
commercially available in Australia and validated for horses 200. An alternative assay is an RIA 
which has also been validated for horses 64. The latter is reported to have different reference 
intervals to the CLIA 220. Banse et al 234 compared both assays and found that there was poor 
agreement between the tests. As such, results should not be considered comparable.  Those 
authors also suggested that the ACTH assay may measure more than the functional ACTH1-39 
fragment, leading to false positives 234. Knowles et al 235 reported a large positive bias using the 
CLIA in autumn in non-laminitic ponies in comparison to an immunoassay. Significant differences 
were not observed in spring. The authors suggested that cross-reactivity with circannually 
variable POMC-derivatives, such as CLIP, might be responsible for this difference. Whether this 
non-specific cross-reactivity explains some of the spurious elevations observed is unknown.  
 
1.3.4.7 TRH stimulation test 
The TRH-stimulation test (measuring ACTH) is a development of the now superseded TRH-
stimulation test of cortisol 236. The latter suffered from variability associated with cortisol 
measurement 4 and so is no longer recommended. TRH receptor mRNA can be detected in both 
the pars intermedia and the pars distalis of the equine pituitary gland 199. The end-products of 
this stimulation in healthy horses, however, are α-MSH and ACTH, respectively 199. When TRH 
was injected in post-mortem confirmed normal horses, ACTH concentrations at 10 minutes post 




values can exceed this 158,180. The clinical significance of the latter finding is unconfirmed but may 
relate to earlier stages of PPID, given the correlation between basal ACTH and histopathologic 
findings 170. Given the circannual variability in pars intermedia size 169, it may be that the 
increased variability of post-TRH ACTH concentrations relates to increased variability of TRH 
receptor expression. Others have also suggested individual differences in the secretion of various 
POMC derivatives 237 which may explain some of the variability. 
 
The current cut-off of 100 pg/mL at 10 minutes was derived from Beech et al. 180 although the 
methodology for generation of this cut-off from the data is unclear. That paper originally 
described the 30 minute time-point as not being statistically different from baseline, and thus 
used a cut-off of 35 pg/mL 180. It should be noted that that lab uses a different methodology and 
reference interval 236 to the work presented herein. More recently, 60 or 65 pg/mL at 30 minutes 
were suggested 238. Again, however, the source of this cut-off is not clear from the available data. 
While the concentrations of ACTH obtained 30 minutes after TRH injection in the earlier papers 
fall under 65 pg/mL 180, it is unclear what statistical analyses were performed to obtain this cut-
off. ACTH concentrations increase in response to TRH in all horses, although the responses are 
markedly greater in PPID horses, both with regards to duration and magnitude 180. Overall, it is 
assumed that due to the maximal responses of ACTH to TRH administration within the first few 
minutes post-injection, an arbitrary time point of 10 minutes was chosen to be practical and 
standardized. 
 
Previous literature has used 36 pg/mL at  30 minutes as an ACTH concentration cut-off at 30 
minutes 158,180. This results in a sensitive test (88%), although in that study, 16/60 TRH-stimulation 
tests in clinically normal horses were considered positive (although 3 of these tests occurred 
during autumn), including 2/23 in histologically confirmed normal horses 158. This would likely 
lead to false positive diagnoses which has implications regarding potentially lifelong treatment 
for positive horses. When these histologically-normal horses had α-MSH measured at the same 





1.3.4.7.1 Influences on the TRH-stimulation test 
1.3.4.7.1.1 Effect of dose of TRH 
When using a blanket dose of TRH (1mg) there was no evidence to suggest an influence of body 
mass, condition score or breed (horses vs. ponies) 180. This dose has also been considered as 
saturating or near-saturating for the pituitary gland in vivo 229,239. Furthermore, 1mg is accepted 
as the standard dose regardless of weight 180 and, more recently, 0.5mg has been shown to give 
similar results to 1mg 240,241.  
 
1.3.4.7.1.2 Effect of feeding 
There is literature showing that fasting prior to TRH-stimulation testing may result in 
recategorization of horses (i.e. PPID or normal), although statistically, overall, there was no 
significant difference 215. However, one horse had a discrepancy of 82 pg/mL 215 – other causes 
of this bias cannot be excluded.  
 
1.3.4.7.1.3 Effect of circannual rhythm 
There is scant information available on the effect of time of year on TRH-stimulated ACTH 
concentrations 180,214,242,243. Previous data in one study was log-transformed, from different 
horses and different disease categories, making interpretation difficult 180. In another study 242, 
the variability associated with the points of central tendency were not presented. In addition, the 
post-TRH stimulation testing ACTH concentrations during the dynamic testing time point was 
markedly lower than previously reported in other studies 242. Haffner et al 243 more robustly 
attempted to stratify horse results into two populations based on TRH-stimulation test results in 
autumn. Again, the variability is unclear from the information provided, as is the likelihood of the 
population with higher post-TRH ACTH concentrations having PPID 243. 
Some authors recommend evaluating the test based on changes in daylight hours, rather than a 





1.3.4.7.1.4 Lack of rises 
There are reports of horses having atypical or lower than expected ACTH concentration rises to 
TRH administration 229. The significance of this is unknown but may relate to insulin sensitivity as 
in horses that were insulin resistant there was no substantial ACTH concentration elevation at all 
229.  
 
1.3.4.7.1.5 Concurrent testing 
Concurrent testing with the OST is not recommended at this time as the latter appears to affect 





1.4 Equine Metabolic Syndrome 
Traditionally, EMS was defined as obesity or regional adiposity (Figs. 1.7, 1.8), laminitis or a 
history of laminitis, and insulin resistance/dysregulation 244. More recently, the roles of 
dyslipidaemia 245,246, systemic inflammation 245,247,248, hypertension 249 and infertility 250 have 
been better defined in this disease. Many animals with EMS are classified as ‘easy keepers’, with 
these animals able to maintain or even gain weight eating diets on which other breeds of 
comparable size may lose weight 251. In addition, many clinicians will diagnose this condition a 
priori - that is, before laminitis is ever diagnosed – in acknowledgement of the desire to identify 
at risk animals prior to laminitis development 237,252. Additionally, many clinical signs associated 
with insulin dysregulation such as body condition score, are not useful in non-obese but 
dysregulated animals 42.  
 
 





FIGURE 1.8. REGIONAL ADIPOSITY DEMONSTRATED BY INCREASED TAIL HEAD FAT. 
 
1.4.1 Epidemiology of EMS 
It has been reported that ID can occur in up to 10% of horses 253, although another study in 
Australia has shown that the prevalence of resting hyperinsulinaemia may be as high as 28% 110. 
 
1.4.1.1 Prevalence of obesity 
The prevalence of obesity has been reported from several locations. In a survey of randomly 
chosen clients of first opinion practices in the UK, overall obesity was reported as 31%, with 
ponies being more frequently obese than horses 254. In Scotland, Wyse et al. 255 found that 45% 
of horses were obese out of 319 pleasure horses. The authors identified that owners in this study 
tended to underestimate their horse’s body condition. In Virginia, USA, Thatcher et al. 256 found 
that almost one third of 300 light breed, mature horses were overweight in summer, with almost 




300 randomly chosen horses. Jaqueth et al 258 found that approximately 40% of horses and ponies 
in Maryland, USA are obese. In a recent longitudinal evaluation of laminitis incidence, the 
prevalence of obesity or greater than ideal bodyweight was 72%, with only 27% of animals being 
considered at ideal bodyweight 29. The prevalence in Australia has been reported as 24.5%, 
although ponies were overrepresented in that study 259. In keeping with owner under-recognition 
of laminitis, owners have also been found to underestimate their horses’ body condition 259. The 
prevalence of laminitis amongst EMS horses is unknown although Morgan et al 110 found an 
prevalence of 12% amongst ponies with hyperinsulinaemia. 
 
1.4.2 Signalment 




Leptin is an adipokine that is excreted by adipocytes in a constitutive manner 260. It functions to 
indicate satiety (and hence energy balance) and is important in the maintenance of bodyweight 
260. Leptin concentrations have been shown to increase with obesity 102,114,245. In addition, 
hyperleptinaemia is associated with cellular insulin resistance as evaluated by the complete 
insulin response test (CIRT) 100. In that study, obesity was not associated with 
hyperleptinaemia100. Similarly, in horses with high body conditions, leptin concentrations were 
associated with insulin concentrations and the insulin response to glucose, but not all obese 
horses in that study were hyperleptinaemic 246. Hyperleptinaemia has also been associated with 
obesity and ID as evaluated by the CGIT 261 and insulin concentrations post-TRH, vehicle or 
sulpiride administration 229. However, from a patient-oriented endpoint, leptin has not been 
associated with laminitis in a clinical cohort study 29. 
 
Adiponectin is a cytokine secreted from adipose tissue that is anti-inflammatory and protective 




29,94,264 and this is true independently of leptin concentrations 245. There is some clinical evidence 
showing that adiponectin might not always be associated with body morphometry 29. 
 
Triglycerides (TG) are involved in lipid storage and energy utilisation. One study has 
demonstrated excellent specificity of elevated triglyceride concentrations at discriminating 
between clinically laminitic ponies and healthy ponies 42. Triglycerides were also used as part of 
a scoring system that had a positive predictive value of 78% in differentiating previously laminitic 
from normal ponies 24. A curvilinear relationship between BCS and TG concentration was also 
found by a group of researchers in Australia 265, while increased TG concentrations have been 
identified in previously laminitic ponies in a clinical longitudinal study 94. The authors in the latter 
study suggest that due to overlap between groups, that TG concentration may not be useful as a 
diagnostic test. Hypertriglyceridaemia has also been reported from clinical cases of ID, albeit with 
no evidence of associated clinical disease 266. 
 
1.4.4 Systemic inflammation 
Elzinga et al. 267 found that EMS horses have increased concentrations of inflammatory markers 
including interferon gamma (IFN-γ), interleukin 6 (IL-6), interleukin 1 beta (Il-1β) and tumour 
necrosis factor alpha (TNF-α) 60 minutes after oral CHO challenges. Burns et al  248 evaluated 
mRNA expression from various adipose tissues in both insulin resistant and insulin sensitive 
horses. They found that there was increased mRNA expression for Il-6 and Il-1β in nuchal 
ligament adipose tissue; however, there was no difference between insulin sensitive or resistant 
mares. Thus, while the nuchal ligament adipose tissue may be more likely to have a pro-
inflammatory profile, the significance as it pertains to ID is unknown. Higher concentrations of 
serum amyloid A, a positive acute phase reactant, have been associated with both obesity and 
insulin concentrations in mixed light breed horses 247. The same study failed to identify an 
association between obesity and other inflammatory markers, however. Increased TNF- α 
concentrations have been associated with IR 41,268, although there was no difference in other 
inflammatory markers in two studies of previously laminitic and normal ponies 41,94. In the Wray 




between groups may relate to the strict management of the previously laminitic ponies aimed at 
reducing its recurrence. 
 
1.4.5 Cardiovascular changes 
Equine metabolic syndrome has also been associated with effects on the cardiovascular system. 
In one group of age- and body condition-matched ponies, ID was associated with hypertension 
during summer 249. Conversely, clinically laminitic ponies have been shown to be relatively 
hypotensive, in comparison to non- and previously-laminitic ponies 42. The cause of this 
phenomenon is unknown, although there was considerable overlap in blood pressure values 
between groups and this was a relatively closed population. However, laminitic ponies were also 
shown to have lower blood pressure than normal ponies after insulin administration 269, which 
may support this phenomenon. While these ponies did not have ‘gold-standard’ assessment of 
their ID status, they did have versions of insulin response tests, with all laminitic ponies having 
reduced glucose responses to insulin injection 269. More recently, myocardial hypertrophy has 
been identified in ponies with EMS and with relative cardiac wall thickness correlated with serum 
insulin concentrations 270. 
 
1.4.6 Influences on insulin regulation 
1.4.6.1 Season 
There is conflicting literature on the effects of season on insulin sensitivity and regulation. Banse 
et al 39, Bailey et al 249 and Place et al 207 found no significant difference in basal insulin 
concentrations between seasons whereas Beech et al 133 found higher insulin concentrations in 
summer and Hart et al 139 and Wray et al 94 found higher concentrations in spring. Borer et al 99 
found that insulin peaks were higher and more variable during autumn, and that ponies were 
more insulin resistant during winter 271. Beythien et al 272 recently found seasonal changes in 
insulin concentrations in response to a modified in-feed glucose test (IFGT) during summer while 
Funk et al 273 found no significant seasonal differences in combined glucose-insulin tolerance 
test (CGIT) results in normal horses. Using the HEC, Fitzgerald et al 274 found that horses became 




times during the year and found higher concentrations in summer, however the horses in that 
paper were exercised in the non-summer months, and thus its effects may be responsible for the 
apparent circannual differences observed in that paper. DeBoer et al 276 found higher insulin and 
glucose responses to cool-season grass ingestion in autumn and spring. Schreiber et al 204 found 
a poor overall seasonal response, although individual animals had more variability in autumn and 
early winter, with one horse have markedly elevated concentrations during this time, and low 
concentrations for the rest of the year. 
 
When NSC concentrations have been evaluated concurrently with insulin concentrations, the 
seasonal patterns tend to correlate well in horses kept at pasture 136. Thus, seasonal changes in 
insulin concentrations may be due to circannual changes in NSC concentration. This may account 
for variability between studies. 
 
Regardless of any seasonal effects, it has been shown that there is variation in basal insulin 
concentrations from year to year amongst both normal and previously laminitic ponies 181, as 
well as within a year in clinically normal geldings 204. 
 
Overall, while certain populations may have circannual fluctuations in insulin sensitivity, some of 
this change may relate to other factors such as pregnancy, pasture and feed NSC concentration, 
and PPID comorbidity. 
 
1.4.6.2 Sex 
A difference between sexes in insulin concentrations 139 or insulin responses to a modified IFGT 
272 has not been identified. 
 
1.4.6.3 Age  
Age plays a role in ID. Insulin dynamics may follow a J-curve distribution in horses over their lives 
whereby a nadir occurs after the zero point, with a sharp rise in the curve thereafter. 




life 277. As mature ponies age, insulin sensitivity, as tested by a version of the IFGT, tends to 
decrease 131, while the prevalence of hyperinsulinaemia increases 110,278. Similarly, insulin 
responses to sweet feed have been shown to be higher in older horses 132 and insulin sensitivity 
as measured by the HEC is reduced in older mares 268. Nielsen et al 279 found that older horses 
had higher post-prandial insulin concentrations, although the mature animals ate the meals more 
quickly, possibly confounding the results. Some have suggested that the rate of decline of insulin 
sensitivity may be affected by environment, diet, genetic or other factors 131,280, although much 
of this was supposition based on human data. Given that horses with PPID can be more insulin 
resistant than normal horses 129,133, and the strong association between age and PPID 67, it may 
be that PPID is a potential confounder in some cases. However, when PPID is controlled for, the 
relationship remains true 139. Furthermore, in Standardbred and Thoroughbred horses screened 
for PPID using the DST, age-related effects were found when ID was assessed using the FSIGTT, a 
modified OST and a dietary challenge model 281. In clinical cases, it thus may be important to 
separate PPID effects from true age-related effects. There are also data suggesting a lack of age 
effect on insulin concentrations 202. 
 
1.4.6.4 Pain and disease 
Several researchers have suggested that insulin is not significantly affected by stress and pain. It 
has been postulated that differences in IR testing (specifically a version of an insulin response 
test) were not due to pain or stress associated with laminitis, but were more likely to be 
associated with intrinsic metabolic differences 269. Similarly, hyperinsulinaemia in previously 
laminitic EMS ponies did not correlate with laminitic episodes 207. Additionally, in the 
oligofructose experimental model, Obel grade 3 laminitis was generally only associated with 
small, or no significant, increases in insulin concentrations 48. Similarly, in the hyperinsulinaemic 
model, Obel grade 2 laminitis was experimentally induced, without significant cortisol increases 
95. In a study evaluating the diagnostic accuracy of basal insulin concentrations, no effect of 
current laminitis on insulin concentrations was observed 44. Thus, acute laminitis may not 
preclude testing of ID. Other stressful events such as nasogastric intubation have not been found 




stressful events may affect ID testing using basal testing 257 and dynamic testing such as the OST 
and two-step insulin response test (2SIRT) 283. Others have also found effects of hospitalization 
on ID as measured by the FSIGTT 284, although diet may be a confounding factor in this study. 
Testing should be withheld in the case of severe systemic illness, as the infusion of endotoxin has 
been shown to dramatically lower insulin sensitivity 285, although that study was not formally 
published or peer-reviewed.  
 
Transport and hospitalization are two potential stressors that may affect the assessment of ID as 
it pertains to testing. Bröjer et al 286 evaluated the effects of novel stabling and transportation as 
a simulation of hospitalization and found no effect on either basal insulin concentrations or 
insulin curves as assessed by the CGIT. 
 
1.4.6.5 Time of day 
There is conflicting evidence for a circadian effect on insulin concentrations with one paper 
supporting an effect 93 and another refuting it 287. 
 
1.4.6.6 Pregnancy status 
Pregnant mares have been shown to be more insulin resistant than non-pregnant mares up to 
270 days of gestation, although after this date glucose disposal into the mammary gland is 
improved 288. Another study has also shown that insulin sensitivity (as measured by FSIGTT) is 
lower in mid-gestation in comparison to non-pregnant mares, and that this difference is 
accentuated with the feeding of a high NSC diet 289. Interestingly, mares did not become more 
insulin resistant in later pregnancy without a high NSC diet.  
 
1.4.6.7 Breed and genetics 
There is thought to be a genetic component to ID 24, as a presumed dominant trait with epigenetic 
influences. Recently, a genome-wide associated study found that a gene associated with 




EMS 128. It should be noted that genome-wide association studies, because of their inherent risk 
of a type-I error, are most at risk of irreproducibility 1. 
 
With regards to breed differences, Standardbreds are widely thought of as being insulin sensitive 
96,97. In addition, Quarter Horses are thought to be relatively insulin sensitive in comparison to 
other breeds 39,40. This appears to be exaggerated in those Quarter Horses who have 
polysaccharide storage myopathy (PSSM), a disease associated with insulin sensitivity 290. There 
are reports, however, of EMS-affected Quarter Horses, and their crosses 139. Ponies 96,133,291,292 
and Andalusians 96 are considered relatively insulin resistant or dysregulated and this IR state was 
found in animals not previously adapted to a high NSC diet. Icelandic horses have been shown to 
be less insulin sensitive than Standardbreds 251,286 while warmbloods are more insulin sensitive 
than ponies 291. Tinworth et al 292 found that ponies were more insulin dysregulated than horses, 
although body condition was an important potential confounder in that study. Thoroughbreds 
are generally thought of as being relatively insulin sensitive 278, although they can certainly be 
susceptible to ID with (in)appropriate management 72,74,293. It should be noted that even 
Standardbreds have been shown to have cellular IR when tested by the FSIGTT 294. The breed 
difference does not appear to be related to differences in feed digestibility 251. 
 
1.4.6.8 Obesity 
Obesity is commonly associated with ID (Fig. 1.9) 24,47,72,73,139,251,261,268. More than half of over-
conditioned ponies were insulin dysregulated as assessed by a modified IFGT by one research 
group 47,295. Using the HEC, obesity markedly reduces insulin sensitivity in comparison to lean 
animals 296, while similar findings have been found using the FSIGTT 72. In a survey of mixed, light-
breed horses, obesity was positively correlated with body condition 247. In a survey of an inbred 
group of native UK ponies 9, those animals predisposed to laminitis were more likely to be obese 
and insulin dysregulated as assessed by proxy analysis. However, the association has been found 
to vary between populations. Obesity may lead to cellular IR through one or both of two 




due to their accumulation in insulin-sensitive tissues. There is some data suggesting that obesity 
has a greater influence on insulin sensitivity in younger mares in comparison to older mares 268. 
 
1.4.6.8.1 Insulin dysregulation without obesity 
There are several studies demonstrating that ID can occur in animals of normal body condition, 
depending on various factors 72,74,249,297–299. Bailey et al 249 compared non-obese, age-matched 
ponies with or without previous laminitis, and demonstrated differences in insulin sensitivity 
based on the reciprocal of the square root of insulin (RISQI) and the modified insulin-glucose 
ratio (MIRG) despite their body conditions. Similarly, differences in insulin sensitivity between 
ponies having previously been diagnosed with laminitis and control ponies were identified when 
fed fructans or administered dexamethasone 297. In one study, previously laminitic ponies tended 
to be of leaner body condition than normal ponies, with neither group being obese 181. 
Interestingly, one group found IR, as measured by the HEC, at both ends of the body condition 
spectrum, including in underweight animals 274. Morgan et al 110 found that, in a survey of 188 
ponies, body condition was not associated with insulin status. 
 
Postulated reasons for the development of ID in the absence of obesity include animals that have 
previously been obese and whose weight is being managed through diet and exercise 298, animals 
who have regional adiposity without obesity 127,298, and the effects of NSC on the enteroinsular 
axis in the absence of excess calorific intake 72,74,297. 
 
1.4.6.8.2 Obesity without insulin dysregulation 
There is also evidence that insulin dysregulation need not be present in all obese animals. 
Bamford et al 102 induced obesity through high fat diets without inducing ID. It should be noted 
that the obesity in this study should was of a short-term nature, which may not fully allow for the 
development of IR over time. Quinn et al 293 found that mature Thoroughbred geldings fed high 
NSC or high fat diets gained weight but only the high NSC diet induced changes in insulin 
sensitivity; this study was performed over a longer period than the Bamford et al study. Another 





FIGURE 1.9. PUTATIVE RELATIONSHIPS AMONG HYPERINSULINAEMIA, OBESITY, INSULIN RESISTANCE AND THE 
EXACERBATING FACTORS OF PREGNANCY, INFLAMMATION AND PPID (MODIFIED FROM FRANK AND TADROS 2014 33). 
 
breed horses were evaluated for IR based on the FSIGTT, obese but insulin sensitive horses were 
identified 248. When a high fat diet was used to induce weight gain in Standardbreds, no change 
in insulin sensitivity measured by the HEC was observed 300, although these effects should be 
repeated in laminitis-susceptibility animals. In a study comparing insulin concentrations to CGIT 




association between obesity and basal insulin concentrations in light breed horses 278. Perhaps 
most clinically relevant, in a prospective, longitudinal study of 446 ponies, body morphometry 
was not associated with the risk of developing laminitis over three years 29. 
 
1.4.6.9 Exogenous and endogenous glucocorticoids 
Exogenous steroid administration has been shown to result in ID 284,297,301–303. In one paper 
examining the effects of topical dexamethasone therapy on various hormone concentrations, a 
relatively conservative dexamethasone dose (17mg total per day) lead to markedly elevated 
insulin concentrations (>300 μU/mL) that persisted for several days post-administration 301. 
These Thoroughbreds had surprisingly high basal insulin concentrations, however, and so there 
may have been an element of underlying ID. In addition, they were fed concentrates 
(composition unknown) three times daily 301 which may have induced the condition 72,74,293,304 . 
Regardless, steroid administration has been shown to induce ID in breeds considered insulin 
sensitive 303,305. Another paper evaluating IR in non-obese ponies demonstrated ‘unmasking’ of 
an insulin resistant phenotype after dexamethasone administration as part of a DST 297. Brennan 
and Urschel 302 demonstrated that a 21 day course of oral dexamethasone resulted in elevated 
insulin concentrations for three days after dexamethasone cessation and abnormal proxy indices 
for between four and 15 days while Tiley et al 303 described increased insulin concentrations 
during a course of the same in healthy Standardbreds on a low NSC diet. Unfortunately, that 
paper did not evaluate the duration of the effect after cessation of the medication. Even a single 
dose of dexamethasone leads to ID  as assessed but the CGIT, although the effect typically lasts 
less than three days 184. 
 
The relationship of endogenous glucocorticoids, outwith that investigated with regards to 
perceived external stress [see section 1.4.6.4. Pain and disease], has not been fully elucidated. 
There is evidence showing that while total cortisol concentrations between healthy and 
hyperinsulinaemic (both PPID and EMS) horses are similar, free cortisol fractions are higher in 
the latter group 139. The authors hypothesized that this may be directly related to obesity (as 




associated with mild inflammation. However, that study found a stronger association with body 
condition than ID, and so its relevance to the development of ID in PPID or EMS is unclear. Others 
have confirmed the lack of a relationship between total cortisol concentrations and EMS status 
207. 
 
The mechanism of ID development secondary to glucocorticoids is incompletely defined. 
Glucocorticoids counter insulin’s effects by altering GLUT-4 membrane expression peripherally 
(leading to cellular IR), as well as stimulating hepatic gluconeogenesis, leading to hyperglycaemia 
and subsequent hyperinsulinaemia 139. Altered 11-β-HSD1 activity in PPID or EMS may also lead 
to altered total or free cortisol concentrations, further leading to ID 139 
 
1.4.6.10 Sepsis 
Infusion of lipopolysaccharide (LPS) is a reliable method for inducing ID, with a 75% reduction in 
insulin sensitivity as measured by the FSIGTT demonstrated 24 hours after its infusion into lean, 
healthy horses 306. A second study identified similar changes 20 hours post-LPS infusion 284. 
Another study has replicated this effect, as measured by the HEC 307, with a potentially biphasic 
response reported. When LPS infusion has been performed in both healthy and EMS horses, 
greater reductions in insulin sensitivity were identified in EMS horses 308. As in interesting aside, 
in the Tóth et al. study 284, pretreatment with thyroxine, a commonly prescribed medication for 
EMS in certain parts of the world, mitigated the effects of LPS on insulin sensitivity. The clinical 
significance of this is unknown however, as few septic patients would be concurrently pretreated 
with thyroxine, and an immediate effect of treatment may not occur. 
 
1.4.6.11 Diet  
While obesity has been associated with insulin dysregulation [see section 1.4.6.8 Obesity], it may 






The feeding of NSCs can cause both obesity 73,245,293 as well as ID 72–74,78,281,297,300. When horses or 
ponies are fed high calorie diets consisting primarily of fat and fibre (and thus low in NSCs), these 
animals become obese, but do not develop ID 245,293. If they are exercised and thus remain the 
same body mass, the results are similar 309. Similarly, when ponies are randomized to isoenergetic 
fat and fibre- or oat-supplemented rations to which they are acclimatised, higher glucose and 
insulin responses are seen in the oat-supplemented ponies 310. Arabian horses fed isocaloric diets 
rich in either fat and fibre or sugar and starch gained weight on the sugar and starch diet, 
potentially related to the metabolic effect of high glycaemic feed 311. When previously laminitic 
ponies were changed from pasture to hay diets, basal insulin concentrations reduced significantly 
181. Similarly, in an experiment evaluating the effects of obesity and diet on insulin sensitivity, 
when obesity was induced in mature Arabian horses through the feeding of high NSC diets, the 
horses became insulin resistant 73. These geldings then had their obesity maintained through the 
feeding of low NSC hay but their ID status was not different to baseline (i.e. it improved with the 
withdrawal of high concentrations of NSCs in the diet) 73. The feeding of fructans leads to a 
marked increase in IR in previously laminitic non-obese ponies, but not significantly so in ponies 
with no history of laminitis 297. When hay with a high NSC concentration was fed to both normal 
and PSSM-affected horses, higher insulin concentrations were observed than when a low NSC 
hay was fed 290. One confounding factor in the latter study was that the high NSC hay was eaten 
more quickly than the low NSC hay. Others have also confirmed that hays of different types 
induce different insulin and glucose responses 276. Another study evaluating the effects of high 
NSC diets on insulin receptor expression revealed no difference between basal insulin 
concentrations in both lean and obese ponies, but did reveal an increase in both groups within 
seven days of beginning the high NSC diet 81. Importantly, the control ponies (both lean and 
obese, and kept on a high fat and fibre diet) had no significant increase in basal insulin 
concentrations over the same period 81. It should be noted that four ponies in this study 
developed clinical laminitis after ingestion of the high NSC diet, but the oligofructose 
concentration ingested was lower 81 than that previously used to induce laminitis through caecal 
dysfunction 48. The effect seems to be somewhat variable between studies, however, with one 




insulin sensitivity can occur after the feeding of high NSC diets for as little as four 296 to six 312 
weeks. 
 
The opposite has also been seen – that a reduction in dietary NSCs can lead to improved insulin 
sensitivity or insulin responses. In an experiment evaluating the effects of exercise on insulin 
sensitivity and bodyweight in ponies, dietary modification alone resulted in comparable weight 
loss and improvements in insulin responses to a modified IFGT 312. Similarly when previously 
laminitic ponies are fed hay instead of high NSC grass, their insulin concentrations lower to being 
clinically similar to ponies with no previous history of laminitis 297. When Standardbreds were 
moved to pasture after having gained weight with a high fat diet, their insulin concentrations 
decreased 300. However, the change in housing (and thus potentially exercise) may have 
confounded these results. Alternatively, as no further weight gain occurred whilst at pasture, the 
diets may not have been isocaloric. It is estimated that a 50% reduction in dietary NSCs would 
result in a 25% reduction in insulin responses 294. 
 
Dietary sugar has been found to reduce insulin sensitivity as assessed by FSIGTT or HEC even in 
relatively insulin-sensitive breeds, such as Thoroughbreds 72,74,281,293 and Standardbreds 78,281, 
respectively. This effect appears to be repeatable when using basal glucose and insulin 
concentrations in Thoroughbred mares fed high-starch diets long-term 304. Interestingly, dietary 
influences on insulin sensitivity appear to be more influential than that of breed 294. 
 
Glucose bioavailability has also been shown to be higher in insulin dysregulated ponies in 
comparison to normal ponies 77. Given the relative importance of glucose-mediated insulin 
release in horses 77, this may explain some of the breed susceptibility differences observed. In 
addition, it has been shown that GLP-2 is increased in ponies with ID 127, and this incretin may 





Fasting can lead to decreased insulin sensitivity in as few as 3 283 to 8 313 to 12 283,314 hours, when 
evaluate as part of basal or dynamic ID testing, although one study found no effect of prior fasting 
on insulin concentrations 295. 
 
Dietary fat may have some modulating effects on insulin dysregulation, aside from its ability to 
provide energy in a low-CHO diet. Fish oil added to the diet of exercising Thoroughbreds and 
Standardbreds lead to trends towards lower insulin and glucose concentrations, although the 
results were not statistically significant 315. Additionally, in another study of exercising horses, 
dietary fat reduced insulin concentrations when combined with exercise, although not at rest 316. 
Psyllium has been reported to have some modulating effects on insulin concentrations, despite 
having almost 25% NSC 317. The study may be misleading, however, as the control diet was grain-
based with approximately 43% NSC. 
 
1.4.6.12 Biologic variability 
Borer et al 99 noted considerable variation of basal glucose and insulin concentrations when 
assessed during different seasons with different diets, with AUC of insulin over 60 hours varying 
by more than six-fold in normal ponies 
 
1.4.6.13 Exercise 
Several postulated mechanisms for improved insulin sensitivity associated with exercise have 
been proposed. These include a) a reduction in muscle and liver glycogen; b) increased insulin 
receptor binding of insulin; and c) increased GLUT expression in skeletal muscle leading to 
increased glucose uptake peripherally 296. 
 
However, in vivo, the effects of exercise on measures of ID are controversial. Exercise has been 
shown to lower insulin concentrations, although the decrease persisted only for the day of 
exercise in one study 318, and for less than that in another 319. Conversely, when evaluating insulin 
responses to an IFGT, reduced responses were seen when ponies were exercised five days per 




exercise 312. Turner et al. 275 confirmed that as little as 15 days of exercise can reduce fasting 
insulin concentrations, although paddock turnout alone is unlikely to be effective. Similarly, when 
evaluated using the HEC, obese and non-obese mares had improved insulin sensitivities that 
persisted for up to nine days after cessation of exercise 296. Menzies-Gow et al 264 demonstrated 
that post-exercise spikes in plasma insulin concentration were less marked after 14 days of low-
intensity exercise in non-laminitic and previously laminitic ponies, as well as finding an acute 
reduction during exercise. Insulin sensitivity has been shown to improve during moderate 
intensity exercise in endurance horses 311, over and above the effects of diet. The same group 
has also found similar results in Thoroughbreds despite weight gain 293, and mixed, unknown 
breeds of horses at both low and moderate intensities of exercise 275. Exercise may also be able 
to mitigate some of the IR induced by a high NSC diet with weight gain 78,311. A recent paper 
described the use of a novel feeding device designed to increased daily exercise and showed that 
weight loss was improved in those ponies that used this device 265. However, in keeping with the 
literature on diet and obesity, while exercise may reduce bodyweight over time, it is unlikely to 
lead to additional improvements in insulin regulation status over a low NSC diet alone 265,318. 
There is also literature demonstrating no effect of exercise on insulin dynamics 287,320. 
 
1.4.7 Testing of insulin dysregulation 
1.4.7.1 Basal insulin 
Basal hyperinsulinaemia, particularly after fasting 257, is generally considered specific for ID 44 at 
commonly used cut-offs. While in many populations it is considered insensitive 271,297,321, there 
are data demonstrating that resting hyperinsulinaemia (>32 μU/mL) has been 100% sensitive for 
predicting future laminitis occurrences when exposed to high NSC pastures 42. This study used 
pony breeds considered at risk of ID, however, and may not be representative across all 
populations 42. A more recent Australian study demonstrated that basal insulin concentrations 
(after 12 hours of fasting) greater than or equal to 8.5 μU/mL were associated with the 
development of laminitis in 75% of ponies subsequently exposed to high NSC 91. Limitations of 
using basal insulin concentrations to detect ID mostly reflect its relative insensitivity 44,72,271,297,321 




a sensitivity of 16.5% 44. An ROC in that study identified an insulin concentration of 3.03 μU/mL 
as being the most diagnostically accurate. In this author’s opinion, that cut-off is clinically 
impractical. It should be noted that this paper used a CLIA that has been shown to have a negative 
bias in comparison to the more commonly reported RIA 323–325 [see section 1.4.7.5]. It has been 
also shown that single, random, non-fasting serum insulin concentrations are not necessarily an 
accurate reflection of an individual’s insulin sensitivity 93,280.  
 
There are various influences on endogenous insulin concentrations that may confound resting 
insulin concentrations, as has mostly been described in the previous section (see section 1.4.6 
Influences on insulin dysregulation). Briefly, several factors that have been shown to affect basal 
insulin concentrations include the following:  A high fat diet has been shown to reduce insulin 
concentrations in exercising, but not resting, Thoroughbreds 316. Metformin has been shown to 
reduce fasting insulin responses 305,326, although this effect is not necessarily repeatable when 
assessed using the FSIGTT 327. In Thoroughbreds fed high NSC or fat and fibre diets for eight 
weeks, basal insulin concentrations did not differ between groups, despite differences in insulin 
sensitivity as measured by the FSIGTT 72. Insulin concentrations are often associated with body 
condition score and tend to be higher in obese animals 268. Insulin has also been correlated with 
neck circumference, as a proxy for regional adiposity 261. Insulin sensitivity as assessed by the 
FSIGTT has been found to be lower in obese Thoroughbreds 72. Others have found no effect of 
obesity on either insulin concentrations or results of the CGIT 44. 
 
1.4.7.2 Insulin proxies 
Several proxies for insulin sensitivity have been developed based on basal glucose and insulin 
concentrations. These include the MIRG,  RISQI and the quantitative insulin sensitivity check 
index (QUICKI) 70. The former is used to estimate the beta-cell insulin response to glucose while 
RISQI is used to estimate insulin sensitivity 70. Unfortunately, these proxies cannot accurately 
differentiate between previously laminitic and normal ponies with only small differences 
between, and large variability within, groups 271. Other researchers have also found unacceptable 




correlation, at best, was identified (with an R2 of 0.71 in the best comparison). This is similar to 
the comparison with the FSIGTT in the original paper of their description, where r = 0.77 in the 
best comparison of RISQI to insulin sensitivity 70. In addition, the proxies were not able to 
accurately predict insulin sensitivity changes when a subgroup of Standardbreds underwent 
weight gain 328. Other researchers have described the use of ratios:  the insulin: glucose estimates 
the quantity of insulin per glucose concentration while the glucose: insulin estimates the effect 
of insulin on glucose concentrations 280. In summary, proxies are no better than the non-proxied 
variables from which they are derived 42. 
 
1.4.7.3 Tests of cellular insulin resistance  
1.4.7.3.1 Hyperinsulinaemic euglycaemic clamp test 
The HEC is referred to as one of the ‘gold standards’ for assessing insulin resistance 135,329. A 
modified version has also been used to induce laminitis 62,95. The HEC involves the administration 
of supraphysiologic concentrations of insulin (typically 45 µU/kg followed by 6 µU/kg/min 135). 
Glucose is measured frequently, and a constant rate infusion of glucose administered to maintain 
euglycaemia. Once a steady state is achieved, insulin concentrations are measured on several 
occasions. The quantity of glucose administered is used to calculate the glucose metabolism rate, 
on the assumption that the high insulin concentrations suppress endogenous insulin release 330, 
and accounting for urinary glucose loss 135,291. The glucose metabolism rate to insulin 
concentration ratio is also calculated. The HEC is not considered a clinically practical test and is 
used primarily for research. It is considered more repeatable than the FSIGTT in horses 330. 
However, if glucose concentrations are not effectively ‘clamped’ in steady state, results may not 
accurately represent the true glucose disposal rate 329. Furthermore, higher insulin 
concentrations lead to lower measured insulin sensitivity 111 and so studies using the HEC should 
be critically evaluated prior to their comparison.  
 
1.4.7.3.2 Insulin-modified, frequently sampled IV glucose tolerance test  
The FSIGTT is sometimes considered the alternative ‘gold standard’ method of determining 




advantages over the HEC: it estimates insulin-dependent and -independent glucose utilization 
311, as well as pancreatic beta-cell function 330. It has been argued that it is technically more 
straightforward than the HEC 135 as glucose infusion rates do not have to be continually adjusted 
329. The FSIGTT involves collecting basal samples and then administering a known quantity of 
glucose by IV infusion (typically 0.3 g/kg). Samples are collected every 1-3 minutes until 20 
minutes, at which time insulin is administered IV, typically at 30 µU/kg, with continued frequent 
sampling until 180 minutes 72. Measured variables include glucose and insulin concentrations 72. 
Calculated variables include insulin sensitivity, glucose effectiveness, the acute insulin response 
to glucose and the disposition index 72. This test is also considered a research tool rather than a 
clinical tool. It should be noted that the FSIGTT is an indirect measure of insulin sensitivity 332. 
 
The HEC and FSIGTT have been shown to give results that correlate, but do not necessarily agree 
282. It should be noted that some have argued that neither the HEC or FSIGTT are necessarily 
appropriate for determining ID status. Some authors 333 have argued that the tests are not true 
representations of physiologic processes as the glucose kinetics are in response to typically 
supraphysiologic concentrations of insulin. While the tests might effectively identify cellular IR, 
cases of horses with normal CGIT 77 or HEC 39 results, but with excessive postprandial 
hyperinsulinaemia have been identified [see section 1.2.1 Development of hyperinsulinaemia 
and insulin resistance]. Specifically, they may not adequately assess the role of the enteroinsular 
axis in ID in a particular individual. Additionally, it has been argued that the FSIGTT suffers at 
extremes of insulin sensitivity, returning potentially nonsensical values 332, and so is best reserved 
for mild cases of IR.  It should also be noted that both of these dynamic tests of insulin sensitivity 
can have significant inter-day variability, with a large reported coefficient of variation (CV) for 
the FSIGTT 330,334. 
 
1.4.7.3.3 Combined glucose-insulin tolerance test  
The CGIT involves the rapid, sequential infusion of glucose and insulin and the frequent 
measurement of blood glucose thereafter 335. The test is characterized by an initial, rapid 




an accurate but straightforward test of IR 335. However, the CGIT has been shown to have 
considerable variability in diagnostic accuracy depending on what cut-offs are used 321. It also 
suffers from inadequate reproducibility 336. The CGIT is typically performed with intermittent IV 
sampling, although a subcutaneous glucose monitor has been used successfully to perform a 
modified version of the test, with a 15-minute lag time suggested to compare with IV glucose 
samples 337.  
 
1.4.7.3.4 Complete and 2-step insulin response test 
The CIRT (also known as the insulin tolerance test) was developed as an assessment of insulin 
sensitivity that was more easily performed in a clinical setting 100. The test involves measuring 
blood glucose before, and frequently after, insulin administration 100. In that paper, a variety of 
doses of insulin were administered to both normal and hyperleptinaemic horses and their 
glucose concentrations (as a direct response) determined. Horses that were hyperleptinaemic 
showed clear separation from those that had normal leptin concentrations. The authors also 
evaluated the reproducibility of the test four months later, using the 40- and 50-minute time 
points post-insulin. Interestingly, they found that all horses were less insulin sensitive, although 
variations in pasture NSC content may have affected results. The authors deemed the test results 
appropriately reproducible; although the test results over time were correlated, there was bias 
present that might make comparisons between time points difficult in individual horses.  
 
The 2SIRT was first described as an abbreviated version of the CIRT 338. The test involves the 
measurement of effect of insulin on glucose concentrations, as a measure of tissue insulin 
sensitivity, at one time point (30 minutes after insulin injection) instead of at multiple times 338. 
The authors described complete separation between insulin resistant and sensitive horses based 
on the 2SIRT 338. However, this was an anticipated response given that the horses were initially 
categorized using the CIRT. Of note, the median time to less than 50% of basal glucose 
concentrations was less than 30 minutes in insulin sensitive horses; this may have implications 
for the repeatability of the 30-minute testing time point. The true ID status of the horses in a 




‘gold standard’. Interestingly, in the same paper, the glucose responses to insulin were not 
reproducible between fasting periods with many horses having different categorical results 283. 
Fasting has been shown to affect the 2SIRT, with reduced glucose responses to insulin injections 
observed after 12-13 hours of fasting 283,314. This was also observed in an older study 339 where 
plasma glucose concentrations were reduced by 72% in fed ponies after insulin administration, 
in comparison to only 30% when the ponies were fasted for three days. The cause of this may 
relate to a relatively increased GI absorption of volatile fatty acids and a relatively reduced GI 
absorption of NSCs, reduced hepatic glycogen stores or altered endogenous insulin 
concentrations 283. As expected, sympathetic responses (in this case mimicked by exogenous 
adrenaline administration) increase insulin insensitivity, although this effect was mitigated by 
exercise due to increased muscular GLUT-4 expression 314. Sympathetic responses should 
perhaps be avoided prior to testing for cellular IR. 
 
1.4.7.4 Tests of the enteroinsular axis  
1.4.7.4.1 Oral sugar test 
The OST was first described as a practical method of assessing insulin dysregulation in a field 
setting 340. It is primarily a test of pancreatic beta-cell responsiveness 88. The original study 340 
compared EMS horses and controls and differentiated them based on their insulin responses to 
a brand of corn syrupb. The paper described the administration of 0.15 mL/kg corn syrup to fasted 
horses, and the subsequent measurement of serum insulin concentrations at 60 and 90 minutes 
post-syrup. However, selection bias may confound the conclusions drawn in this paper. The 
control group consisted of Quarter Horses, which have been recognized as being relatively insulin 
sensitive 39,40. In contrast, the EMS group consisted of several breeds overrepresented in 
epidemiological studies of laminitis [see section 1.4.6.7 Breed and genetics]. Thus, the differences 
between groups may represent intrinsic breed differences rather than disease states. In another 
paper examining the effects of fasting on the OST 283, insulin concentrations after corn syrup 
administration were much lower in a group containing Thoroughbreds than in the original paper. 
Similarly, in a paper examining the incretin effect  of glucose administration 89, normal horses 





The OST appears to be specific, but insensitive when evaluating horses for ID 88,321. The original 
paper compared the OST results to those of an intravenous glucose tolerance test in the same 
animals 340. There was considerable overlap in the area under the curve (AUC) of insulin in the 
OST results, despite separation in the glucose tolerance test results , as well as large intrahorse 
variability in the OST results in normal horses 340. When the OST has been compared to the HEC, 
no significant relationship was found between the tests 39, although other authors have argued 
good correlation exists between results of a modified OST and insulin-dependent glucose 
disposal rates 88. When compared to the FSIGTT, poor correlation was also found 321, although 
some variability exists between studies and calculated variabilities 40. Specifically, all horses in 
the former study were classes as having normal insulin responses to the corn syrup despite 
several being classed as insulin resistant based on the FSIGTT; sensitivities of 0% and 14% were 
found in the latter study using insulin cut-offs of 60 μU/mL and 45 μU/mL, respectively. 
Interestingly, more recent research by the group that first described the OST has defined ID 
horses using means that were below the original cutoff 341. The same research group later 
evaluated the repeatability of the OST in two different populations in both control and EMS 
horses 140. The investigators found that there was agreement between insulin concentrations in 
between 83 and 91% of test results. However, the 95% CI of the mean biases were markedly 
wide, making the true repeatability of the test poorer than was reported. Indeed, the authors 
state that the OST may not be useful for horses with results near the cut-off, and that individual 
insulin results vary too much for monitoring the response to any management or therapy 140. 
Another study by the group also suggested that variable insulin concentrations as part of the OST 
are due to within-horse variability 215. The potentially poor reproducibility of the test has been 
further shown in ponies subjected to four tests over three weeks using slightly different testing 
conditions 313. In that study, inadequate agreement between samples taken at the same time 
points in the same animals were found, along with wide limits of agreement and large CV. 
Minimal increases in insulin concentrations have also been seen in ponies in a modified version 
of the OST 342. This same modified OST found satisfactory diagnostic accuracy in comparison to 




ponies were used as the EMS group. This OST also had less than satisfactory repeatability, with 
relatively high mean CVs for both TMax and CMax of insulin. When compared to the FSIGTT, this 
modified OST has been shown to be poorer at evaluating changes in insulin sensitivity at or near 
the normal sensitivity range 88, suggesting that it is not accurate at detecting mild disease.  
 
Varied dosing 343 (up to 0.45 mL/kg) and insulin cut-offs 40 (normal < 30.2 μU/mL when 
administered at 0.25 mL/kg) have been recently described for the OST which may be more 
reproducible in other populations, although the follow-up work by Frank and Walsh 140 found 
poor repeatability despite using a lower cut-off. This less-than-satisfactory repeatability has also 
been demonstrated elsewhere when using higher doses of corn syrup 343. The authors of that 
paper suggested that the diagnostic accuracy of the test could be improved by calculating the 
AUC of insulin over at least three measurements, although this may be impractical in a clinical 
setting. Poor repeatability has been found elsewhere 313. 
 
In keeping with the effects of fasting on the 2SIRT, fasting for greater than 3 283 to 8 313 hours has 
been shown to increase stimulated insulin concentrations, with potential increases in insulin 
concentrations of 40 µU/mL estimated in some cases after fasting 313. Interestingly, significant 
increases in insulin concentrations post-syrup administration were not observed in non-fasted 
horses, although most of these horses would not be considered to be predisposed to ID 283. Again, 
however, the true ID status of these horses was not assessed by a current ‘gold standard’. 
Interestingly, the effect of fasting on OST results were disputed by another study recently, with 
only small effects on glucose concentrations observed in some horses 215. The same study did not 
identify differences in insulin concentrations when the OST was performed concurrently with the 
TRH-stimulation test 215. 
 
There is no apparent effect of season on results of the OST 39, although results were not available 
for the entire year and only five horses were assessed. In agreement with the original paper 
describing the OST 340, when Quarter Horses were assessed to evaluate the effects of pasture 




horses as insulin dysregulated 39.  Results were similar when horses were tested at pasture and 
while stabled 39. 
 
There may be breed differences with regards to the time to maximum post-syrup insulin 
concentrations in the OST with longer (approx. 68 minutes) and shorter (approx. 58 minutes) 
TMax seen in horses and ponies, respectively 344. Knowles et al 313 found that the most common 
time to the CMAx of insulin was 30 minutes, in contrast with the original study in horses 340. 
 
1.4.7.4.2 In-feed glucose test 
The IFGT has been described using 0.75 g/kg 292,345, 1 g/kg 99 and 1.5 g/kg 96 bodyweight (bwt) 
glucose. It was originally used to evaluate small intestinal absorption of glucose 346 but has more 
recently been used to characterize insulin responses to known quantities of glucose 96,99,292,345. 
At 1.5 g/kg, the IFGT was moderately well correlated with results from the FSIGTT 96. There is 
some evidence that the IFGT can predict 32,91 or categorise 99 horses and ponies at risk of laminitis 
(a more patient-oriented outcome than simply ID). Of interest, the insulin cut-offs that separated 
previously-laminitic ponies and normal ponies in a recent study 99 were much higher than the 
cut-off used to classify a horse as insulin dysregulated 68. From personal observations, some 
horses do not eat the entire glucose-containing meal either at all, or sufficiently quickly. While 
cut-offs are also available for a lower dose of glucose (0.5 g/kg bwt) 68, the recent description of 
a lower dose of glucose leading to similar insulin concentrations 345 is a potentially helpful 
modification. The authors of that study actually reported lower insulin concentrations in ponies 
that ate the larger dose of glucose (1 g/kg bwt) and attributed this to slower meal consumption 
345. The IFGT has also been shown to be a repeatable test 345, arguably more so than the OST 140. 
 
Younger horses have been shown to have a longer time to peak insulin after ingestion of various 
high NSC meals 279 (as a proxy IFGT), while different CHO sources also lead to various TMax in the 
same study. A variant of the IFGT (with the glucose administered by NGT), insulin concentrations 
at two hours were well correlated with those of the FSIGTT and insulin sensitivity as measured 




concentrations were able to characterise not only the risk of laminitis, but also the speed of onset 
of disease 91. While not an orthodox IFGT, this nevertheless demonstrates the use of post-NSC 
insulin measurement. 
 
The OST and IFGT have been directly compared, albeit in ponies of previously unknown ID status 
344. This study found that results were not completely comparable, with the IFGT categorising 
more animals as insulin dysregulated. The IFGT did have more variability, but importantly had 
larger insulin concentrations and AUC in comparison to the OST 344. 
 
While enteroinsular axis testing might better evaluate the natural pathophysiology of disease 77, 
concerns exist about confounding factors on glucose absorption, and hence insulin release. These 
include rates of feed consumption, gastric emptying and intestinal absorption 88,277,329.  
 
1.4.7.5 Insulin assays and sample handling 
Insulin is a relatively stable analyte. When stored at room temperature for up to 3 days, either 
centrifuged and separated or in whole blood, there was no significant difference in comparison 
to results obtained, in the same clinical cases, after immediate centrifugation and refrigeration 
347. In that study, the largest bias observed was 2 μU/mL, which would not be clinically significant. 
 
From a research point of view, the Siemens Coat-a-Count RIAc is one of the most frequently cited 
methodology for insulin concentration determination in horses 79,81,94,99,184,279,287,303,317,323,340,348. 
This RIA is not available in Australia. In clinical practice, a CLIAa is available at several commercial 
laboratories. The precision of this assay, as determined by its intraassay CV, is considered 
excellent 323. The CLIA has been used in clinical research involving hyperinsulinaemia secondary 
to oral glucose intake 77 and in generating reference intervals for ACTH in ponies 202. When 
comparing the CLIA with the RIA, Banse et al 348 found that the CLIA had a positive bias (i.e. gave 
higher concentrations) of approximately 13 μU/mL. It should be noted that when 5 discordant 
results were removed, the bias was considered clinically insignificant 348. Both tests in that paper 




linearity 349. That paper did describe a technique of improving the performance of the assay by 
using charcoal-stripped plasma, which subsequently was superior to the Mercodia ELISA as well 
as other ELISAs. Interestingly, that paper demonstrated only moderate concordance between the 
RIA and the ‘gold standard’ of mass spectrometry/gas chromatography. In contrast, a more 
recent paper comparing the same CLIA and RIA identified a negative bias at lower concentrations, 
but confirmed the positive bias at higher concentrations 323. This negative bias has been 
corroborated in another study comparing the CLIA to two different RIAs 324 and in another study 





1.5 Manufacturers’ Details 
aImmulite 1000/2000, Siemens Healthcare Pty Ltd, Bayswater, VIC, Australia 
bKaro light corn syrup; ACH Food Companies, Inc, Memphis, TN, USA 
cSiemens Coat-A-Count Insulin Radioimmunoassay, Siemens Medical Solutions Diagnostics, Los 
Angeles, CA, USA 
dBio-One 4 mL plastic whole blood tube with spray-coated K2EDTA, Greiner, Germany 
eTRH, Sigma Pharmaceuticals Ltd, North Liberty, IA, USA 
fBio-One 4 mL plastic whole blood tube with spray-coated K2EDTA, Greiner, Germany 
gMedcalc Statistical Software version 16.4.3, MedCalc Software, Ostend, Belgium 
hRStudio, R Studio Inc, Boston, MA, USA 
iSealed Envelope Ltd, www.sealedenvelope.com  
jAccutrend Plus, Roche Diagnostics, Risch-Rotkreuz, Switzerland 






Endogenous ACTH is a readily available method to diagnose PPID in Australia. However, 
diagnostic uncertainty can arise when endogenous ACTH concentrations fail to clearly 
characterise a horse as either PPID-positive, or PPID-negative. As PPID exists as a continuum of 
disease 173, early recognition of disease might be difficult. A so-called ‘grey zone’ can be described 
when ACTH concentrations fall near the upper cut-off limit 212, particularly given the numerous 
non-PPID influences on ACTH concentrations, as previously discussed. The interpretation of 
results within a ‘grey zone’ depends on the pre-test probability of disease in an individual and 
the likelihood ratios of a test. Based on existing published literature 64,66,130,200, positive likelihood 
ratios during the quiescent phase and dynamic phases are 3.36 and 20, respectively. Negative 
likelihood ratios during the quiescent and dynamic phases are 0.21 and 0, respectively. Assuming 
a pre-test probability of 20% (based on a prevalence of approximately the same 66), and using the 
two-step Fagan’s nomogram 350, this would translate into the following approximate post-test 
probabilities: positive test during the quiescent phase – 48%; positive test during the dynamic 
phase – 83%; negative test during the quiescent phase – 6%; and, negative test during the 
dynamic phase – 0%. Thus, while negative tests perform adequately, positive tests, particularly 
during the quiescent phase, may not be appropriate in subclinical cases. 
 
The TRH-stimulation test holds promise as an alternative test to endogenous ACTH. Although 
there is some data from the northern hemisphere proposing diagnostic cut-offs for the dynamic 
phase for ACTH concentrations post-TRH administration 243, a consensus has yet to be reached. 
Diagnostic cut-offs and seasonality of the TRH-stimulation test have not been reported in the 
southern hemisphere. Recent data at this institution and by others suggest geographic location 
affects basal endogenous ACTH upper reference limits 66,210,211. While this may be due entirely to 
photoperiod differences, geographic or other climactic influences may also be involved. Previous 
research has identified differences in basal pars intermedia secretions in different locations and 





Previous work on the effects of feeding on basal ACTH concentrations has demonstrated mixed 
results 214,215. It is unknown if the CHO administered in the OST affect ACTH concentrations. 
Furthermore, it has been shown that intravenous insulin can increase ACTH concentrations 226, 
but this effect as part of the 2SIRT is unknown. This may have implications for field-based testing 
with regard to the timing of blood collection for ACTH determination, such as where basal insulin 
is omitted during an OST, or if a TRH-stimulation test is to be combined with the 2SIRT. 
 
Finally, performing diagnostic test experiments in different locales using different testing 







The aims of this study are to better characterize the results of various tests of endocrine causes 
of laminitis in an Australian setting, and to evaluate their reproducibility. The study is designed 
to reflect clinical practice in Australia, using resources that are widely available in this country.  
 
The aims of the study are as follows: 
- to characterise the endogenous plasma ACTH response to TRH-stimulation during both 
phases of the circannual pituitary cycle in a group of clinically normal horses in two 
disparate geographic and climatic locations in Australia; 
- to assess the reproducibility of the OST and 2SIRT in a group of horses of unknown ID 
status; 
- to determine the repeatability of the 2SIRT when glucose samples are obtained at 25, 30 
and 35 min post-insulin (to allow for imperfect field testing conditions); and 
- to determine the effects of OST and 2SIRT testing on ACTH concentrations thus 
determining the suitability of post-test sampling in diagnosing concurrent PPID. 
 
1.6.2 Hypotheses 
The hypotheses of the study are as follows: 
- that there will be a significant difference between the plasma ACTH concentrations at 10 
min and 30 min post-TRH administration between the dynamic phase and the quiescent 
phase of the circannual pituitary cycle; 
- that the 2SIRT will be poorly reproducible, that there will be differences between results 
of the 2SIRT when testing at different post-insulin time points, and that there will be 
significant effects of the test protocol on ACTH concentrations; and 
- that the OST will be poorly reproducible, and that there will be significant effects of the 
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Thyrotropin releasing hormone-stimulation (TRH) testing for pituitary pars intermedia 
dysfunction (PPID) is recommended at times when pituitary gland activity is quiescent. Current 
diagnostic cut-offs reflect testing in the northern hemisphere during this time. The objectives of 
this study were to evaluate TRH-stimulation testing during two different phases of the circannual 
pituitary cycle, and to determine whether diagnostic cut-offs developed in the northern 
hemisphere are appropriate in Australia. Thirteen clinically normal horses at Perth and 23 at 
Townsville had TRH-stimulation tests performed during the quiescent and dynamic phases of the 
circannual pituitary cycle. At both locations, post-TRH adrenocorticotropic hormone (ACTH) 
concentrations were significantly different between testing time points (Perth P=0.001; 
Townsville P<0.0001).  In Perth, the mean ACTH concentrations 10 min post-TRH during the 
quiescent and dynamic phase were 51.4 pg/mL (95% CI 46.4-56.4) and 248.5 pg/mL (95% CI 
170.2- 326.9) respectively. The median percentage change in ACTH concentrations between T0 
and T10 in the dynamic phase was 361.9%. In Townsville, the mean ACTH concentrations 30 min 
post-TRH during the quiescent and dynamic phase were 35.3 pg/mL (95% CI 29.6 to 40.9) and 
112.3 pg/mL (95% CI 93.4 to 131.2), respectively.  The median percentage change in ACTH 
concentrations in the dynamic phase was 144.7%. The ACTH cut-off after TRH-stimulation in 
normal horses during the quiescent phase in Perth and Townsville appears similar to the values 
established in the northern hemisphere. However, TRH-stimulation testing during the dynamic 
phase was extremely variable at both locations, complicating its interpretation at this time of 
year.  
 





The circannual pituitary pars intermedia cycle affects basal adrenocorticotropic hormone (ACTH) 
concentrations in both normal horses and horses with pituitary pars intermedia dysfunction 
(PPID) 133,183,185,189,207,211,238. More recently, this circannual cycle has been linked to changes in 
daylight length 209,210, although other factors may also influence this rhythm. Broadly, between 
the summer and the winter solstice, endogenous ACTH concentrations increase, reach a peak 
(acrophase) and then decline – this is defined by the authors as the dynamic phase 210. In contrast, 
a relatively quiescent phase is apparent when endogenous ACTH concentrations are lower and 
display reduced variability compared to the rest of the year, and occurs between the winter and 
summer solstices 179,210,351. There are increased ACTH responses to thyrotropin releasing 
hormone (TRH) administration during the dynamic period of the circannual pituitary cycle in 
clinically normal horses compared to the quiescent period of the cycle 180,214,242. 
 
The ACTH response to TRH administration is a more sensitive test for PPID than basal endogenous 
ACTH at certain times of the circannual pituitary pars intermedia cycle (Beech et al., 2007, 2011a, 
2011b). Several studies have shown that ACTH concentrations peak in less than 15 min post-TRH 
administration 158,180,236. Current recommendations in the northern hemisphere support a 
diagnostic cut-off of 110 pg/mL ACTH at 10 min and 65 pg/mL ACTH at 30 min post-TRH 
administration 238.The test may be used to differentiate normal horses from PPID-affected horses 
whose basal endogenous ACTH concentrations fall within a ‘grey-zone’ 179. In contrast to basal 
endogenous ACTH testing, TRH-stimulation testing is currently recommended at times when 
ACTH concentrations are quiescent 238.  
 
Although there is some data from the northern hemisphere proposing diagnostic cut-offs for the 
dynamic phase 243, a consensus has yet to be reached. Diagnostic cut-offs and seasonality of the 
TRH-stimulation test have not been reported in the southern hemisphere. Recent data by the 
authors and others suggest geographic location affects basal endogenous ACTH upper reference 
limits 189,210. While this may be due entirely to photoperiod differences, geographic or other 




pars intermedia secretions in different locations and climates (McFarlane et al., 2011), although 
their relative effects could not be separated. 
 
The aim of the study was to characterise the endogenous plasma ACTH response to TRH-
stimulation during both phases of the circannual pituitary pars intermedia cycle in a group of 
clinically normal horses in two disparate geographic and climactic locations in Australia. The 
hypothesis was that there would be a significant difference between the plasma ACTH 
concentrations at 10 min (T10) and 30 min (T30) post-TRH administration between the dynamic 
phase and the quiescent phase.  
 
2.3 Materials and methods 
2.3.1 Horses 
The study protocol was approved by the animal ethics committees of Murdoch University 
(R2702/14 8 December 2014) and James Cook University (A2127 7 November 2014). Horses were 
selected at each of two geographical locations within Australia; Perth in southern Australia 
(31°57’S, 115°52’E; considered a hot-summer Mediterranean climate) and Townsville in northern 
Australia (19°26’S, 146°81E; considered a tropical savanna climate). In Perth, 13 horses were 
tested once in September 2015 and once in March 2016. Horses were chosen on the basis of age 
(< 15 years), lack of clinical signs of PPID and normal basal quiescent & dynamic phase 
endogenous ACTH concentrations 210. There were five Thoroughbreds (four geldings and one 
mare) and eight Standardbreds (four geldings and four mares). The mean age (range) was 10.4 
(4-14) years. All horses were clinically well for at least six months prior to each time point. Horses 
were housed in irrigated Kikuyu pasture in larger herds all year round with supplemental oaten 
hay. All horses were in moderate body condition at both testing times (body condition score 
median 5/9 (range 4-6] 352) when tested by two independent observers.  
 
In Townsville, 23 horses were tested once in September 2015 and once in April 2016. Horses were 




dynamic phase ACTH concentrations 210. Breeds represented were Thoroughbreds (n = 14; 13 
mares, one stallion), Standardbreds (n = 5; mares), Quarter Horses (n = 3; mares) and an 
Australian Stock Horses (n = 1; mare). The mean (range) age of these horses was 11.4 (3-17) years. 
All horses were clinically well for at least six months prior to each time point. Horses were dry lot 
paddock housed and received supplemental feed of roughage only or a balanced pelleted ration 
and roughage depending on their level of physical activity. Horses were body condition scored 
during the April testing period by two independent observers with the median body condition 
score being 6/9 (range 4-8) 352. 
 
2.3.2 Experimental Methodology 
Horses were normally housed together in paddocks and were moved to smaller paddocks 
together on the morning of each test day at least 2 h prior to testing being performed. Evidence 
of excessive exercise or physiologic stress was not observed in any of the horses. No 
supplemental feed (other than pasture) was supplied for the duration of the test20. The horses 
were regularly housed as such as part of their teaching duties and were considered acclimatized 
to this procedure. The TRH-stimulation test was performed as previously described 180. Blood was 
collected into sterile plastic vacutainer tubes containing ethylenediamenetetraacetic acid 
(EDTA)d for measurement of ACTH concentrations prior to intravenous injection of 1 mg of TRHe. 
The TRH was reconstituted under a laminar flow hood with sterile water for injection to a final 
concentration of 1 mg of TRH/mL. The solution was filtered with a 0.22-μm syringe filter and 
stored in 1 mL aliquots at –80 °C until use (2-9 months). Blood was again collected into sterile 
plastic vacutainer tubesf containing EDTA at 10 min (Perth) or 30 min (Townsville) post-TRH 
injection and immediately placed on ice. The horses were monitored for 1-2 h and returned to 
their respective herds thereafter. The samples were centrifuged in a refrigerated centrifuge for 
5 min at 4000 g within 2 h of collection. The plasma was then separated and frozen at -80 °C until 
analysis. Plasma samples were transported on dry ice and ACTH concentrations analysed using a 
chemiluminescent assaya previously validated for use with equine plasma. Quality control 
materials provided by the manufacturer were used daily. The interassay coefficients of variation 





2.3.3 Statistical analysis 
The data were assessed for normality using the Shapiro-Wilk test; all raw data were normally 
distributed either before or after logarithmic transformation. Normally distributed data are 
presented as means (± standard deviations; SD) or means (range). The data for percentage 
change in ACTH concentration, evaluated between T0 and T10 or T30 at each time point, were 
not normally distributed and are presented as median (range). A paired, two-tailed t-test was 
performed to determine if a difference existed between the T10 or T30 ACTH concentrations in 
the dynamic and quiescent time points at each location. An unpaired two-tailed t-test was 
performed to compare basal ACTH concentrations between Perth and Townsville at both the 
quiescent and dynamic time points. A Wilcoxon signed-rank test was performed to determine if 
there were differences in the percentage increase in ACTH concentration after TRH stimulation 
between testing time points at each location. Statistical significance was set at P<0.05. All 
statistical analyses were performed on commercially available softwareg,h.   
 
2.4 Results   
Four horses had one to two coughs post-TRH administration. No other adverse effects were 
noted. In Perth, all basal ACTH concentrations were within previously published reference 
intervals during both the quiescent and dynamic phases of the circannual pituitary pars 
intermedia cycle at this location 210 . Results are presented in Table 1 and Fig. 1. The T10 ACTH 
concentrations in September were all below the upper reference limit (110 pg/mL) previously 
described in clinically normal horses 238. The T10 ACTH concentrations in March were significantly 
higher than the T10 ACTH concentrations in September (P=0.0001). The median percentage 
changes (Table 2) between time points were significantly different (P<0.0001). 
 
For Townsville, results are presented in Table 3 and Fig. 2. All basal ACTH concentrations were 
within previously published reference intervals during both the quiescent and dynamic phases of 
circannual pituitary pars intermedia cycle at this location 210. All but one T30 ACTH concentration 




min post-TRH ACTH concentration of 68 pg/mL. This horse was characterised as normal based on 
monthly ACTH concentrations and the proximity to the previously described decision limit and 
subsequently included in further analysis. The T30 ACTH concentrations in April were significantly 
higher than the T30 ACTH concentrations in September (P<0.0001). The median percentage 
change (Table 2) between time points were significantly different (P<0.001). 
 
Basal T0 ACTH concentrations at each time point were significantly different between sites during 




When TRH-stimulation tests were performed in a group of clinically normal horses with a low 
likelihood of PPID in two geographic locations in Australia during the quiescent phase 
(September) of the circannual pituitary pars intermedia cycle, the ACTH concentrations were 
consistent with those previously reported for normal horses as confirmed by pituitary histology 
180,236. This is of note as the reference intervals for basal ACTH concentrations at these locations 
in Australia differ from other locations (in the northern hemisphere) where the TRH-stimulated 
ACTH concentration cut-offs have been created 210,238. However, despite the low variability, too 
few horses were tested at 10 min post-TRH administration to determine a more robust reference 
interval. Specifically, Friedrichs et al. (2012) recommend that a minimum of 20 animals, and 
ideally 40, be used to create reference intervals.  
 
The results of the TRH-stimulation tests performed at March in Perth and April in Townsville 
suggest these time points are within the dynamic phase of the circannual pituitary cycle as 
marked variation in post-TRH ACTH concentrations occurs. Although a recent abstract 243 
suggested post-TRH cut-offs during the dynamic phase of the circannual pituitary cycle, the study 
numbers were small. Another study evaluated circannual ACTH concentration responses to TRH 
administration and found marked dynamic phase variability in ACTH concentrations, regardless 




in this study, further work is required to determine the results of TRH-stimulation testing in PPID 
horses during the dynamic phase of the circannual pituitary cycle.  
 
We also examined the percentage change in ACTH pre- and post-TRH administration. In both 
locations, the percentage change was significantly different between the quiescent and dynamic 
time points. Our results support the premise that percentage change in ACTH post-TRH 
administration is affected by circannual cycle and is in agreement with Diez de Castro and 
colleagues 214.  However, these results are in contrast to Funk and colleagues 242 where the 
percentage change in ACTH after stimulation with TRH did not appear to be affected by the 
circannual rhythm. The reason for this is unknown, although the latter study had lower ACTH 
responses to TRH than the current study and used a different ACTH assay. From these data, it 
may not be appropriate to use percentage change in ACTH concentrations as a method of 
diagnosing PPID in horses having undergone TRH stimulation tests. 
 
The marked variability in endogenous ACTH post-TRH stimulation during the dynamic phase of 
the circannual pituitary cycle may make testing and interpreting results of a TRH-stimulation test 
in this phase difficult. Several studies have reported the results of TRH-stimulation tests 
performed in clinically normal horses during the dynamic phase and also demonstrated variability 
180,203,242,243. Apart from time of year, variability in resting ACTH concentrations may be caused by 
breed 151,185, time of day 224, stress 219, illness 221, long-distance transport 206,353, feeding 214, 
laminitis 219 & high intensity exercise 193,354, as well as PPID. Causes of variability in TRH-stimulated 
ACTH concentrations other than time of year and PPID are unknown. All of the horses studied 
were free of clinical signs of disease, fed only pasture, did not exercise within 2 h of sample 
collection and were housed in a manner to which they were acclimatized. Furthermore, the basal 
concentrations obtained in this study demonstrated little variability. While it is thought that the 
circannual pituitary cycle may be related to changes in photoperiod 209,210, geographic or other 
environmental factors may contribute to the observed variations. When the circannual pituitary 
cycle has been evaluated in other parts of the world, less obvious circannual differences have 




Schreiber et al., 2012; Florida, USA – McFarlane et al., 2011; Townsville, Australia - Secombe et 
al., 2017), which might reflect changes in photoperiod. 
 
Several horses had normal results but with minimal ACTH elevations post-TRH administration. 
This has been reported elsewhere 242. The cause is unknown but may relate to altered TRH 
receptor expression in the pituitary gland or temporary exhaustion of ACTH stores at the time of 
TRH administration. The TRH receptor mRNA has been identified in tissue explants of both the 
pars intermedia and pars distalis. In normal horses, TRH-stimulated ACTH derives from the pars 
distalis, while in PPID horses it derives from the pars intermedia (McFarlane et al., 2006). Given 
the circannual variability in pars intermedia size (Cordero et al., 2012), it may be that the 
increased variability of post-TRH ACTH concentrations relates to increased variability of TRH 
receptor expression. Others have also suggested individual differences in the secretion of various 
pro-opiomelanocortin derivatives (Sojka-Kritchevsky and Johnson, 2014) which may explain 
some of the variability. 
 
The horses used in our study were not confirmed to be free of PPID based on histology. However, 
they all had 12 months of ACTH measurement, all of which were deemed to be within normal 
limits of previously determined regional and seasonal reference intervals  210. Additionally, the 
results of the TRH-stimulation tests during the quiescent phase are similar to those obtained in 
histologically normal horses 158,180.   
 
There are several limitations associated with this study that may reduce its external validity. 
Unfortunately, standardisation of testing times was not achieved. Logistical limitations did not 
enable T10 testing in Townsville. However, T30 testing results may still be clinically useful in 
situations where T10 testing is missed. The literature to date supports an early ACTH peak post-
TRH injection of less than 15 min 158,180,236. Furthermore, during the quiescent phase, the 
difference between normal and PPID horses is greatest at 10 min post-TRH injection 158,180,236. 




circannually between these locations 210, the effect of location on post-TRH ACTH concentrations 
is still unknown. Testing at both time points in both locations would have allowed analysis of this. 
 
Only two time points during the year were investigated for logistical reasons. It has recently been 
shown 209,210 that the circannual rise and fall in ACTH concentrations occurs over a longer phase, 
with a more gradual rise and steeper fall, than what is considered autumn. The purpose of this 
paper was not to determine monthly ACTH responses to TRH stimulation. However, given that 
the length of each phase may vary with geographic location, more complete characterisation of 
the ACTH response to TRH throughout the year may be important with regards to testing at 
transition times between the quiescent and dynamic phases.  
 
2.6 Conclusions  
In this population of clinically normal horses in Australia, TRH-stimulation testing during the 
dynamic phase of the circannual pituitary pars intermedia cycle demonstrated marked variability. 
In contrast, and similar to other locations, TRH-stimulation testing during the quiescent phase 
demonstrated lower variability and existing cut-off values as recommended by the Equine 
Endocrinology Group appear applicable. Significant differences were identified between post-
TRH ACTH concentrations at both locations during the dynamic phase. Variability in the dynamic 
phase results makes interpreting results and proposing a point estimate cut-off at which a horse 
would be considered to have a normal test result difficult. Until TRH-stimulation tests are 
performed on large numbers of PPID-confirmed horses to establish appropriate diagnostic cut-
offs, basal ACTH concentrations measured during the dynamic phase and TRH-stimulation tests 
performed during the quiescent phase may be more appropriate for the diagnosis of PPID, 




2.7 Table 1 
Means, 95% CI of the means and ranges of ACTH concentrations for both the dynamic phase and 
quiescent phase TRH-stimulation tests in Perth.  
 
  








n 13 13 13 13 
Mean 26.7 51.4 49.6 248.5 
95% CI 24.0 to 29.3 46.4 to 56.4 43.5 to 55.7 170.2 to 326.9 
Minimum 18.9 36.0 35.6 80.7 




2.8 Table 2 
Median (range) percentage increases in ACTH concentrations after TRH administration during the 
dynamic and quiescent phases at both locations. Note that Perth post-TRH samples were 
collected at 10 min and Townsville post-TRH samples were collected at 30 min. The median 
percentage change was significantly different between testing time points at each location. 
  
  Quiescent Perth Dynamic Perth Quiescent Townsville Dynamic Townsville 
n 13 13 23 23 
Median 85.8 361.9 40.0 144.7 
Minimum 33.5 68.8 -35.1 -7.2 




2.9 Table 3 
Means, 95% CI of the means and ranges of ACTH concentrations for both the dynamic phase and 












n 23 23 23 23 
Mean 24.0* 35.3* 49.3 112.3 
95% CI 20.4 to 27.6* 29.6 to 40.9* 41.7 to 56.9 93.4 to 131.2 
Minimum 14.7 18.1 25.6 53.6 




2.10 Figure 1 
Box and whisker plot of quiescent (September) and dynamic (March) phase TRH-stimulation 
testing in Perth. Individual results are denoted by shapes. The box denotes the first and third 
quartiles and the bars denote the inner fences. The central line in the box is the median. The 
horizontal line denotes the suggested cut-off at 10 minutes post-TRH administration in the 






2.11 Figure 2 
Box and whisker plot of quiescent (September-November) and dynamic (April) phase TRH-
stimulation testing in Townsville. Individual results are denoted by shapes. The box denotes the 
first and third quartiles and the bars denote the inner fences. The central line in the box is the 
median. The horizontal line denotes the suggested cut-off at 30 minutes post-TRH 
administration during the quiescent phase in the northern hemisphere. 
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Insulin dysregulation can occur concurrently with PPID. Field-testing methods of detecting insulin 
dysregulation should be reproducible in a variety of populations. The objectives of this study 
were to determine the effects of insulin dysregulation testing using a two-step insulin response 
test (IRT) on ACTH concentrations and to determine the reproducibility of this test. A group of 15 
Thoroughbred and Standardbred horses underwent an 2SIRT three times, at weekly intervals. For 
one week, ACTH was measured at the basal and testing time points in this group and in an 
additional control group of 15 horses. Agreement was deemed satisfactory when a difference 
beyond twice that of the standard deviation of the mean would not result in clinically significant 
differences. There was unsatisfactory agreement between the glucose concentrations at 25, 30 
and 35 min post-insulin. There was unsatisfactory agreement of the test results between weeks. 
There was no clinically significant difference in ACTH concentrations before and at 30 min post-
insulin (P = 0.05). A limitation of the study is that selection bias limits external validity in the 
target population. Our results indicate that the 2SIRT is not adequately reproducible. The test did 






The recognition of insulin dysregulation is essential in the management of laminitis 33. Current 
methods to assess insulin dysregulation involve stimulation of the enteroinsular axis (in addition 
to blood glucose-mediated insulin release) or evaluation of the cellular response to insulin with 
some authors suggesting testing both aspects of insulin dysregulation in horses suspected of 
having endocrinopathic laminitis 237.  
 
Reproducibility refers to the precision of the results of tests carried out under changing 
conditions of measurement 2. These changing conditions may refer to different times of testing, 
locations, populations tested, or laboratory instruments used. This may be relevant in cases 
where different laboratory assays are available, for instance, or to assess biologic variability over 
different weeks. Testing of the cellular response to insulin, namely the ability of endogenous or 
exogenous insulin to maintain normoglycaemia, can be achieved via several methods 70,296,330,331. 
The two-step insulin response test (IRT) was developed from the complete insulin response test 
100 as a practical means of assessing whole body glucose responses to exogenous insulin. It 
involves measuring basal glucose, administering regular insulin, measuring glucose 30 min after 
insulin administration, and expressing the results as a ratio where a result > 0.5 suggests insulin 
resistance 338. While the 2SIRT has not been validated against the frequently-sampled insulin-
modified glucose tolerance test  (FSIGTT) or the hyperinsulinaemic euglycaemic clamp test (HEC; 
both considered the ‘gold-standards’ for assessing insulin sensitivity 329,355), the parent complete 
insulin response test has been shown to correctly identify horses as being either insulin sensitive 
or resistant 100. The test offers a rapid, inexpensive assessment of insulin dysregulation with near-
instant results which is attractive from a practical point of view. The complete insulin response 
test described testing glucose at 15, 30 & 45 min post-insulin administration 100. The 2SIRT further 
refined this to testing glucose levels prior to, and 30 min post-insulin administration 338. However, 
it is unknown how imprecision of the 30 min post-insulin administration sampling time point 
would affect the interpretation of the test results (i.e. if the sample was taken at 25 or 35 min 





Insulin dysregulation is also a component of pituitary pars intermedia dysfunction (PPID) 135. 
Testing for PPID most commonly relies on basal endogenous adrenocorticotropic hormone 
(ACTH) concentrations 189,211. There are various elucidated influences on ACTH concentrations 
194,203,214,219,221 but the effects of insulin dysregulation testing on ACTH concentrations require 
evaluation. Specifically, previous work has shown that intravenous insulin can increase ACTH 
concentrations 226, but this effect as part of the 2SIRT is unknown. This may have implications for 
field-based testing with regard to the timing of blood collection for ACTH determination. 
 
The study was designed to reflect clinical practice in Australia, using resources that are widely 
available in this country. The first aim of this experiment was to assess the reproducibility of the 
2SIRT in a group of horses of unknown insulin dysregulation status. A second aim was to 
determine the repeatability of the 2SIRT when glucose samples were obtained at 25, 30 and 35 
min post-insulin (to allow for imperfect field testing conditions). The final aim was to determine 
the effects of testing on ACTH concentrations thus determining the suitability of post-test 
sampling in diagnosing concurrent PPID. Our hypotheses were that the 2SIRT would be poorly 
reproducible, that there would be differences between results of the 2SIRT when testing at 
different post-insulin time points, and that there would be significant effects of the test protocol 
on ACTH concentrations.  
 
3.3 Materials & methods 




Thirty horses of unknown insulin dysregulation status underwent testing in August (southern 
hemisphere winter). Horses were randomly assignedi with blocking by age into equally-sized 
treatment (test) or control (sham test) groups. Thirty horses were chosen on the basis of a priori 
power calculations using existing ACTH concentration variability 211,214,236 , to reject the null 




regards to ACTH concentrations post-2SIRT with a power of 0.8 and alpha set to p < 0.05. Three 
replicates of the 2SIRT over three weeks were chosen to allow evaluation of fixed and random 
effects. Horses with historical or current evidence of laminitis (based on clinical examination and 
foot radiography where necessary) were excluded due to its potential confounding effects on 
ACTH concentrations 219. Horses were also excluded if they demonstrated clinical signs of PPID; 
a subset of the horses had monthly ACTH testing and TRH-stimulation testing with results 
supportive of disease-free status 180,189,210,211 . There were 12 Thoroughbreds (six geldings & six 
mares) & 18 Standardbreds (seven geldings & 11 mares). The mean age (± SD) was 14 (± 5) years. 
All horses were clinically well for at least six months prior to the study. Horses were housed in 
irrigated Kikuyu pasture in larger herds all year round with supplemental ryegrass hay. All horses 
were in moderate body condition (body condition scores 4-6/9 352). The mean (± SD) body weight 
was 564 (± 33) kg.  
 
3.3.2 Experimental design 
Horses were housed in paddocks together on the morning of each test day. No supplemental 
feed (other than pasture) was supplied for the duration of the test. The horses were regularly 
housed as such as part of their teaching duties and were considered acclimatized to this 
procedure. To minimise the effects of exercise from moving paddocks on ACTH concentrations, 
testing began at least two hours after movement to the test paddock 193,319,354.  
 
All horses had either a real or sham 2SIRT as per randomisation. The 2SIRT was performed as 
previously described 338. Venous blood was obtained by direct venepuncture using a 21-gauge 
needle and blood glucose determined by use of a handheld glucometerj previously validated for 
use in horses 305. Direct venepuncture was chosen to best reflect standard clinical practice. Fifty 
units of regular insulink were administered intravenously using the same venepuncture. Control 
horses were administered 0.5 mL of saline intravenously. To assess the repeatability of the 30-
min glucose result of the 2SIRT (T30) in the treatment group, glucose samples were measured 
from whole blood at 25 (T25), 30 and 35 (T35) min post-insulin administration. Basal and T30 




and immediately placed on ice. The samples were centrifuged in a refrigerated centrifuge for five 
minutes at 4° C at 4600g within two hours of collection. The plasma was then separated and 
frozen at -80° C until analysis. Blood glucose concentrations were monitored for at least 30 min 
after insulin administration or until normal. Intravenous 50% glucose was available for rapid 
administration in case of clinical signs of hypoglycaemia. A high energy grain feed was provided 
to all horses once the 35-min glucose sample had been collected. To assess the reproducibility of 
the IRT, the treatment horses underwent testing under the same conditions at one-week 
intervals, for a total of three tests. 
 
3.3.3 Laboratory assays 
Concentrations of ACTH were measured using a chemiluminescent assaya as previously described 
200,211 . The coefficients of variation (CV) for lower and upper level quality control materials were 
4.16% and 5.07% respectively. The analytical sensitivity was 9 pg/L.  
 
3.3.4 Statistical analysis 
Data were assessed for normality using the Shapiro-Wilk test. If normality was not met, then a 
reciprocal transformation was used to achieve normality of data.  Random glucose samples were 
assessed in duplicate or triplicate to ascertain the CV of the glucometer. The CV of the glucometer 
was 6%.  
 
To determine if ACTH concentrations before and after each test were significantly different, a 
mixed model ANOVA was used, with time (pre- and post-test) as the within-subject measure and 
the test group (treatment vs control) as the between-subject measure. Box’s Test of Equality of 
Covariance Matrices were performed to confirm that the ANOVA assumptions were met for each 
test.  
 
A linear mixed effects model was used to examine whether there was an effect of time (between 
weeks 1, 2 and 3) on the results of the IRT. Time (weekly replicates) and breed of horse were 




basal glucose levels over three weekly replications (week 1, week 2 and week 3). Agreement 
analysis based on the method suggested by Bland and Altman 356 was performed to examine 
whether week 1, week 2 and week 3 measurements were in agreement with each other. We 
performed three agreement tests: week 1 and week 2, week 1 and week 3 and finally week 2 and 
week 3. Mean values of the differences for each combination of weeks, lower and upper 
agreement levels for each combination of weeks and 95% confidence intervals for the mean 
differences, upper agreement levels and lower agreement levels were obtained. Agreement was 
deemed satisfactory when a difference beyond twice that of the standard deviation of the mean 
would not result in clinically significant differences 356. 
 
For all tests, statistical significance was set at P < 0.05. All statistics were performed on 
commercially available software packagesg,h. 
 
3.4 Results 
All data were available for 12 horses in the treatment group that underwent repeated testing, 
with one week’s data missing for one horse and two weeks’ data missing for two horses. Horses 
with incomplete data were excluded from the analysis. Data were available for all but five horse-
week T30 glucose replications. Four horses developed blood glucose concentrations less than 1.1 
mmol/L during testing. However, no clinical signs of hypoglycaemia were observed. There was 
insufficient agreement between T25, T30 and T35 during each week of testing (Tables 1-3). Nine 
out of 15 horses were classed as insulin resistant in at least one week 338 . Only seven horses were 
categorized the same (either insulin resistant or insulin sensitive) each week. The mean glucose 
ratio for week 1 was significantly different to week 2 (P = 0.04) but not week 3 (P > 0.05). No 
effect of breed was identified (P = 0.18). Agreement was not satisfactory between weeks (Table 
4).  
 
The mixed model assumptions evaluating the effects of the 2SIRT on ACTH concentrations were 
met (P = 0.975). There was a significant difference in the mean ACTH concentration between the 




for the treatment group; fig. 1). There was no significant difference in mean ACTH concentrations 
between the two test (treatment and control) groups of horses (P = 0.5). Finally, there was no 




In this population of horses, the 2SIRT was not adequately reproducible. The 2SIRT was assessed 
continuously (using the individual ratios), whereas the original paper describes a categorical 
cutoff with results >0.5 indicating insulin resistance 338. Recent data have shown that, particularly 
using categorical cut-offs, some horses can have inconsistent classifications 283. It was decided to 
use continuous data in case there were horses that had similar results centred around the cutoff, 
thus increasing the chances of finding the test reproducible. Indeed, some horses crossed 
categories each week or had ratios equal to 0.5. Even allowing for this, there was insufficient 
agreement between weeks. Overall, there was insufficient agreement between glucose 
concentrations obtained at T25, T30 and T35. This suggests that being consistent regarding the 
post-insulin glucose measurement timing is important when comparing tests for individual 
animals. This study did demonstrate the safety of the 2SIRT when being performed in presumed 
insulin sensitive horses. 
 
Given that most of these horses have had several negative OSTs [see Chapter 4], it is difficult to 
determine the clinical significance of one or several positive 2SIRTs in this population of horses. 
Based on the findings here, more research is required to determine the accuracy and 
appropriateness of the 2SIRT in evaluating clinical laminitic cases for underlying ID. Causes of 
poor reproducibility might relate to endogenous sympathetic drive (e.g. from venepuncture or 
herd dynamics), insulin bioavailability differences or variable fasting 283,314. 
 
Field-based tests such as these are important to develop and validate as the current ‘gold-
standard’ tests are logistically challenging and not relevant for clinical practice. Some have argued 




329,355. Furthermore, excessive post-prandial hyperinsulinaemia may occur prior to the 
development of tissue insulin resistance 33, suggesting that some horses may have normal HEC 
or FSIGTT but have a higher risk of laminitis nonetheless.  
 
We found no significant effects of the 2SIRT on ACTH concentrations. Hypoglycaemia secondary 
to intense exercise is associated with increased ACTH concentrations in humans 357, and glucose 
and ACTH concentrations are inversely proportional in foetal sheep 358. It may be that the 
mechanism of hypoglycaemia is more important rather than the absolute concentration, or that 
there are species differences explaining the results. The reason for the increased ACTH 
concentrations observed over time is unknown. These horses were observed continuously during 
the test and there was no perceived illness or physiologic stressor that would increase ACTH 
concentrations 193,354 . While the treatment horses had additional venepunctures to assess the 
reliability of the test, venepuncture alone is unlikely to increase ACTH concentrations significantly 
in most horses 223 , these horses were accustomed to multiple venepunctures and the control 
horses had only one venepuncture. Regardless, the effects are unlikely to lead to recategorisation 
of horses as false positives in the majority of horses given the bias, using regionally appropriate 
reference intervals 210 .  
 
There are several limitations of this research limiting its external validity, chiefly selection bias. 
Standardbreds have been shown to have increased insulin sensitivity in comparison to breeds 
typically affected by endocrinopathic laminitis 96,97. It could be argued that testing should be 
limited to those horse breeds more likely to have genetically-predisposed insulin resistance, 
respectively (i.e. the target population 359). Unfortunately, the study was limited by breed 
availability. The sample in this study, albeit small, could not identify a difference between 
Standardbreds and Thoroughbreds regarding reproducibility of the IRT. Thoroughbreds are not 
typical of the breeds associated with insulin dysregulation 360 but may be susceptible to it under 
certain circumstances 72,74,111. Furthermore, PPID horses were excluded from analysis; the 
response of endogenous ACTH concentrations to exogenous insulin may be different in that 




still relevant that many horses had some or all IRTs give results consistent with evidence of IR. 
Whether this reflects IR in the absence of enteroinsular axis abnormalities, or measurement 
error, or both, is unknown.  
 
3.6 Conclusions 
In this population of horses in Western Australia, the 2SIRT was not adequately reproducible. 






3.7 Table 1 
Agreement analysis for the 2SIRT for week 1 across T25, T30 and T35. Results are expressed as 
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T30 and T35 
-0.225 











3.8 Table 2 
Agreement analysis for the 2SIRT for week 2 across T25, T30 and T35. Results are expressed as 
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T30 and T35 
0.08 











3.9 Table 3 
Agreement analysis for the 2SIRT for week 3 across T25, T30 and T35. Results are expressed as 
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T30 and T35 
0.16 










3.10 Table 4 
Agreement analysis for the 2SIRT. Results are expressed as the ratio of T30 glucose 
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3.11 Figure 1 
Comparison between basal and T30 time points in test and control groups demonstrating no 
significant difference between groups at either test time point (P = 0.54). There was a clinically 
insignificant effect of time on ACTH concentrations, however (P = 0.004). Columns and bars 
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Insulin dysregulation can occur concurrently with PPID. Field-testing methods of detecting insulin 
dysregulation should be reproducible in a variety of populations. The objectives of this study 
were to determine the effects of insulin dysregulation testing using an OST on ACTH 
concentrations and to determine the reproducibility of this test. A group of 15 Thoroughbred and 
Standardbred horses underwent an OST three times, at weekly intervals. For one week, ACTH 
was measured at the basal and testing time points in this group and in an additional control group 
of 15 horses. For the OST, no substantial increase in insulin concentrations was observed in our 
horses. Despite this, there was unsatisfactory agreement of the test results between weeks. 
There was no statistical difference in ACTH concentrations before and at the 60 min post-sugar 
time point. A limitation of the study is there were minimal increases in insulin concentrations in 
response to sugar identified in all horses. In addition, selection bias limits external validity in the 
target population. The results suggest that the OST was not a test likely to detect early ID in this 
population or with this assay, nor was it reproducible. It did not significantly affect ACTH 
concentrations; however, this should be assessed in animals with higher insulin responses to the 







The enteroinsular axis is tested by oral administration of simple carbohydrates 40,96,99,340,343,345. 
The oral sugar test (OST) was originally described 340 in North America using a radioimmunoassay 
that is no longer available in Australia. The test involves administering a specific brand of corn 
syrupb and measuring endogenous insulin concentrations 60 or 90 minutes later 340.  
 
Previous work on the effects of feeding on basal ACTH concentrations has demonstrated mixed 
results 214,215. It is unknown if the carbohydrates administered in the OST affect ACTH 
concentrations. This may be relevant as omission of a basal insulin concentration time point may 
allow owner administration of the corn syrup and thus only one venepuncture by the veterinarian 
60 or 90 minutes later.  
 
The study was designed to reflect clinical practice in Australia, using assays that are widely 
available in this country. The first aim of this experiment was to assess the reproducibility of the 
OST in a group of horses of unknown insulin dysregulation status. A second aim was to determine 
the effects of testing on ACTH concentrations thus determining suitability of post-test sampling 
in diagnosing concurrent PPID.  
 
The hypotheses were that the OST would be poorly reproducible, and that there would be 
significant effects of the test protocol on ACTH concentrations.  
 
4.3 Materials & methods 
4.3.1 Horses 
Thirty horses of unknown insulin dysregulation status underwent oral sugar testing in October or 
December (southern hemisphere spring to summer). Horses were randomly assignedi with 
blocking by age into equally-sized treatment (test) or control (sham test) groups. Groupings were 
the same as in the 2SIRT experiment. Control horses were administered 75 mL water orally. Thirty 
horses were chosen on the basis of a priori power calculations using existing ACTH concentration 




treatment and control groups with regards to ACTH concentrations post-OST with a power of 0.8 
and alpha set to p < 0.05. Three replicates of the OST over three weeks were chosen to allow 
evaluation of fixed and random effects. Horses with historical or current evidence of laminitis 
(based on clinical examination and foot radiography where necessary) were excluded due to its 
potential confounding effects on ACTH concentrations 219. Horses were also excluded if they 
demonstrated clinical signs of PPID; a subset of the horses had monthly ACTH testing and TRH-
stimulation testing with results supportive of disease-free status 180,189,210,211 . There were 12 
Thoroughbreds (6 geldings & 6 mares) & 18 Standardbreds (7 geldings & 11 mares). The mean 
age (± SD) was 14 (± 5) years. All horses were clinically well for at least 6 months prior to the 
study. Horses were housed in irrigated Kikuyu pasture in larger herds all year round with 
supplemental ryegrass hay. All horses were in moderate body condition at both testing times 
(body condition scores 4-6/9 352). The mean (± SD) body weight was 564 (± 33) kg.  
 
4.3.2 Experimental design 
Horses were housed in paddocks together on the morning of each test day. No supplemental 
feed (other than pasture) was supplied for the duration of the test. The horses were regularly 
housed as such as part of their teaching duties and were considered acclimatized to this 
procedure. To minimise the effects of exercise from moving paddocks on ACTH concentrations, 
testing began at least two hours after movement to the test paddock.  
 
All horses had either a real or sham OST in October or December 2015, as per randomisation. The 
OST was performed as previously described 340, with 0.15 mL/kg bodyweight corn syrupb 
administered by dosing syringe. Basal (T0) EDTA and serum samples were collected by plastic 
vacutainer system for measurement of ACTH and insulin concentrations, respectively, prior to 
oral administration of either corn syrup or water, and at 60 min post-administration (T60). Serum 
samples for insulin determination were also obtained at 90 min post-administration (T90). EDTA 
samples were immediately placed on ice. The samples were centrifuged in a refrigerated 
centrifuge for five min at 4° C at 4000g within two hours of collection. The plasma was then 




temperature, were centrifuged and the serum separated and frozen at -80° C until analysis. All 
samples were analysed within 9 months. To assess the reproducibility of the OST, the treatment 
horses underwent testing under the same conditions at one-week intervals, for a total of three 
tests. 
 
4.3.3 Laboratory assays 
Concentrations of ACTH were measured using a chemiluminescent assaya as previously described 
200,211. The coefficients of variation (CV) for lower and upper level quality control materials were 
4.16% and 5.07% respectively. The analytical sensitivity was 9 pg/mL. Insulin concentrations were 
measured using a chemiluminescent assaya as previously described 323. The intra-assay and 
interassay coefficients of variation were both <8%. The analytical sensitivity was 2 μU/mL. 
 
4.3.4 Statistical analysis 
Data were assessed for normality using the Shapiro-Wilk test. If normality was not met then a 
reciprocal transformation was used to achieve normality of data.  
 
To determine if ACTH concentrations before and after each test were significantly different, a 
mixed model ANOVA was used, with time (pre- and post-test) as the within-subject measure and 
the test group (treatment vs control) as the between-subject measure. Box’s Test of Equality of 
Covariance Matrices were performed to confirm that the ANOVA assumptions were met for each 
test.  
 
A linear mixed effects model was used to examine whether there was an effect of time (between 
weeks 1, 2 and 3) on the results of the OST. Time (weekly replicates) and breed of horse were 
treated as fixed effects, horse as the random effect and testing time points (T0, T60 & T90) within 
each week as nested effects.  
 
Results are presented as T60 or T90 insulin concentrations. Agreement analysis based on the 




and week 3 measurements were in agreement with each other. Three agreement tests were 
performed: week 1 and week 2, week 1 and week 3 and finally week 2 and week 3. Mean values 
of the differences for each combination of weeks, lower and upper agreement levels for each 
combination of weeks and 95% confidence intervals for the mean differences, upper agreement 
levels and lower agreement levels were obtained. Agreement was deemed satisfactory when a 
value beyond twice that of the standard deviation of the mean would not results in clinically 
significant differences 356. 
 
For all tests, statistical significance was set at p<0.05. All statistics were performed on 
commercially available software packagesg,h. 
 
4.4 Results 
Data were available for all horses at all time points each week. No adverse effects were noted in 
any horse. Basal insulin concentrations at each week were < 2 μU/mL in all horses. In five horses, 
no insulin response was detected at any time point in any week. The maximum serum insulin in 
any horse at any time point in any week was 26.2 μU/mL. As such, no horse was classed as insulin 
resistant 340. The mean week 2 and week 3 post-syrup insulin concentrations were significantly 
different from week 1 (P = 0.004 and 0.027, respectively).  No effect of breed was identified (P = 
0.06). Agreement was not satisfactory between weeks (Tables 1 and 2). 
 
The mixed model assumptions evaluating the effects of the OST on ACTH concentrations were 
met after the removal of one outlier (P = 0.296). There was no significant difference in the mean 
ACTH concentration between T0 and T60 (P = 0.722; fig. 1). Furthermore, there was no significant 
difference in mean ACTH concentration between test (treatment and control) groups (P = 0.272) 
and no significant interaction effect of time and test group on ACTH levels (P = 0.522). Inclusion 






In this population of horses, the OST was not adequately reproducible. While the absolute T60 
SD were low, this was still deemed unsatisfactory given the low insulin concentrations post-syrup. 
Values less than the lower limit of detection (i.e. with a true value of less than 2 μU/mL) were 
recategorised as being at the lower limit (2 μU/mL). The anticipated effect of this was an increase 
in the reproducibility (and thus potentially a type 1 error). Despite this, in this population, the 
OST does not appear adequately reproducible, as has been found elsewhere in different 
populations of horses 39,313 .  
 
This data also supports the effect of breed on insulin dysregulation, and specifically that this 
group of Thoroughbreds had minimal increases in insulin concentrations in response to oral 
carbohydrates, similarly to Standardbreds 96,97. Given that Thoroughbreds have been shown to 
be affected with laminitis 31 and that insulin dysregulation can be induced in this breed 72,74,293, a 
reliable test of the enteroinsular axis is important for this breed. This may be particularly relevant 
given the anecdotal prevalence of laminitis in Thoroughbred broodmares, and the association of 
pregnancy and insulin dysregulation in this breed 289.  
 
The experimental design was not intended to compare the results of the OST and 2SIRT due to 
the timing of the tests and the potential for effects of season on insulin concentrations 139 . These 
tests have been suggested to have poor agreement with each other 283 , although this has not 
been formally evaluated. The OST has also been compared to the HEC and FSIGTT and has been 
shown to lack agreement 321. Finally, these horses have not been confirmed as being insulin 
sensitive or resistant as per either ‘gold-standard’, making comparison difficult.  
 
The cause of the poor reproducibility in the OST is unknown but likely reflects biological factors, 
possibly involving the enteroinsular axis 77. The source of corn syrup is the same as previously 
described 340. The product was thoroughly mixed and used completely during testing making 
precipitation of sugars unlikely. As mentioned, excessive self-exercise was not observed. Breed 




OST, there was considerable variation in individual horse insulin responses at all time points 
measured. Further work by that group has found poor intrahorse repeatability of individual 
insulin concentrations at various time points when tested twice over 7-14 days in a population of 
horses considered insulin dysregulated 140. While the authors suggested that there was sufficient 
agreement when using a dichotomous outcome, assessment as a continuous variable is 
important for assessing risk of disease (magnitude of increase) and disease progression 
(improvement with management or therapeutic intervention. There may be an effect of breed 
on the OST 40. A recent study evaluated the OST with varying periods of fasting and suggested a 
difference between horses fasted and fed; those authors also found minimal increases in insulin 
concentrations in response to the corn syrup 283. Varied dosing (up to 0.45 mL/kg) and insulin 
cut-offs (normal < 30.2 μU/mL when administered at 0.25 mL/kg) have been recently described 
for the OST which may be more reproducible in other populations 40,343 although the follow-up 
work has revealed only fair to poor repeatability despite using a lower cut-off 140 or higher dose 
343. Interestingly, all of the horses in this study would have been categorised as insulin sensitive 
with the new cut-offs 40, although not all time points were collected.  
 
We found no significant effects of the OST on ACTH concentrations. Part of this may be related 
to the lack of an insulinaemic response. However, in a mixed breed population of unknown insulin 
dysregulation status, it has been shown that basal ACTH concentrations as part of TRH 
stimulation tests were not significantly affected by the OST 215.  
 
An alternative to the OST is the in-feed glucose test (IFGT) although its reproducibility has not 
been completely investigated and there are effects of breed on markers of insulin sensitivity 97, 
although these likely reflect underlying predispositions to ID. The IFGT typically involves 
administering glucose in a non-glycaemic feed and measuring insulin concentrations 
approximately 2 hours later 99. There is literature supporting the reproducibility of the IFGT in 
ponies as well as a variant in-feed test using a pelleted pony cube mix of equivalent energy 345. 




Finally, glucose administered by nasogastric intubation correlates well with the HEC and FSIGTT 
282which may make it a better reflection of the true insulin dysregulation status of the horse. 
 
There are several limitations of this research limiting its external validity, chiefly selection bias. 
However, even in ponies, the currently available data suggests the OST is not adequately 
reproducible 313. Furthermore, this study was not designed to evaluate the accuracy of testing, 
only the reproducibility. Given that the breeds in this study have been extensively used in studies 
used to characterise the OST 88,215,283, it is important to ascertain its validity, even if it would not 
be routinely employed in these breeds clinically. 
 
Poor responses to the OST make interpreting its effects on ACTH concentrations difficult to 
extrapolate to animals that are insulin resistant. It had originally been planned to assess ACTH 
concentrations at T90 for the OST. This was not pursued due to the similar insulin responses 
observed at T60 and T90, and the lack of test effect on ACTH concentrations. Other time points 
should be reassessed in other populations given the data demonstrating differing times of peak 
insulin concentrations between ponies and horses 344. 
 
There are data demonstrating that the chemiluminescent assay used in this study gives lower 
concentrations than radioimmunoassays 323,324. Unfortunately, the Siemens Coat-a-Count assay 
is no longer available in Australia. In contrast, the chemiluminescent assay is widely available in 
Australia, and its use likely represents the most clinically relevant testing method.  
 
4.6 Conclusions 
In this population of horses in Western Australia, the OST is not adequately reproducible. A more 
sensitive test, such as the IFGT or a variant thereof, may be more appropriate. Additionally, the 
insulinaemic responses of Thoroughbreds and Standardbreds to enteral sugars are similarly poor, 
suggesting that these breeds should not be used to validate tests of the enteroinsular axis. Finally, 
there does not appear to be a clinically significant effect of performing the OST on endogenous 




4.7 Table 1 
Agreement analysis for the OST for T60 time points. Results are expressed as insulin 
concentrations in μU/mL. aBack transformed data after log transformation. For the analysis 
between week 1 and week 2, the median of the differenced data was 1.005 μU/mL. In ninety five 
percent of cases, the week 1 median would be between 70% below or 200% above the week 2 
median. For the analysis between week 1 and week 3, the median of the differenced data was 
0.81 μU/mL. In ninety five percent of cases, the week 1 median would be between 20% below or 











limit (95% CI) 
Upper 
agreement 
limit (95% CI) 
Week 1 and 
Week 2 a 
1.005 (median) N/A N/A  N/A 
Week 2 and  
Week 3 a 
0.81 (median) N/A N/A N/A 













4.8 Table 2 
Agreement analysis for the OST for T90 time points. Results are expressed as insulin 










limit (95% CI) 
Upper 
agreement 
limit (95% CI) 































4.9 Figure 1 
Comparison between basal and T60 time points in test and control groups during the oral sugar 
test (with outlier included) demonstrating no significant difference between groups at either test 
time point (P = 0.4272). There was no effect of time (P = 0.722). Columns and bars represent the 






Chapter 5. Discussion 
Pasture-associated laminitis is a debilitating disease of the foot that appears to be triggered by 
ingested simple CHO. Recent research has revealed the important role that insulin plays in the 
induction of laminitis. A genetic predisposition to excessive post-prandial hyperinsulinaemia 
likely results in insulin-mediated laminar pathology and failure, given (in)appropriate 
management conditions.  
 
Insulin responses to oral CHO can also be used to assess and define the risk of laminitis in at-risk 
horses. Categorisation of horses as at-risk, however, relies on correctly identifying them as insulin 
dysregulated. In particular, the detection of excessive post-prandial hyperinsulinaemia may 
remain the most important and clinically relevant method to diagnose ID. In clinical practice, 
horses and ponies at high risk of laminitis might be easy to identify based on signalment, body 
morphology and management conditions. The sensitivity of a diagnostic test affects the post-test 
probability of that horse having that condition. Thus, in horses with a lower pre-test probability, 
more sensitive tests are required to correctly recognize ID in these horses. These tests should be 
satisfactorily reproducible such that changes over time accurately reflect disease state, and 
hopefully laminitis risk, rather than random variability or systematic bias. Furthermore, sensitive 
tests might be useful in detecting insulin dysregulation prior to corticosteroid administration in 
otherwise healthy horses, and thus be part of a risk-benefit analysis prior to therapy. 
 
In this population of horses, the OST was found to not be adequately reproducible. While the 
absolute T60 SD were low, this was still deemed unsatisfactory given the low insulin 
concentrations post-syrup. Values less than the lower limit of detection (i.e. with a true value of 
less than 2 μU/mL) were recategorised as being at the lower limit (2 μU/mL). The anticipated 
effect of this was an increase in the reproducibility (and thus potentially a type 1 error). Despite 
this, in this population, the OST does not appear adequately reproducible, as has been found 
elsewhere in different populations of horses 39,313. While the test may be appropriately sensitive 





The 2SIRT was also found to not be adequately reproducible. It was decided to use continuous 
data in case there were horses that had similar results centred around the cutoff, thus increasing 
the chances of finding the test reproducible. Indeed, some horses crossed categories each week 
or had ratios equal to 0.5. Even allowing for this, there was insufficient agreement between 
weeks. This is disappointing given the practical and straightforward nature of the test, which 
provides results quickly and with minimal equipment. 
 
No significant effects of the 2SIRT or OST on ACTH concentrations were detected. Any observed 
effects are unlikely to lead to recategorisation of horses as false positives in the majority of horses 
given the bias, using regionally appropriate reference intervals. From a clinical perspective, while 
T0 sampling might more accurately represent the true disease status of the horse, post-test 
sampling is likely appropriate. 
 
The results of the OST testing are consistent with minimal increases in insulin concentrations  
identified elsewhere in the literature 39,283. There is likely a breed effect involved 40, although 
insensitivity of the test is also suspected. The exact dose of sugar within the corn syrup used in 
the OST is unknown but was originally thought to be approximately 0.15g/kg of syrup as it was 
originally described 340. Recent work has shown that the concentrations are much lower than this, 
with a higher dose resulting in 160.3 mg/kg bwt of sugars 343 This may explain the poorer insulin 
responses observed in this study and the literature in comparison with those obtained using an 
IFGT, which has a dose of sugar approximately six times higher. The IFGT may also be a more 
flexible test for several reasons. Peak insulin concentrations in one study were found between 
two and four hours post-feed ingestion 99 while in another, 90 minute insulin concentrations were 
not significantly different to two hour concentrations 345. This may allow for more varied testing 
time points. This is in contrast with the OST where insulin concentrations were not different from 
baseline at four hours post-Karo syrup administration 267. In addition, the IFGT, as well as being 
more practical in Australia (with regards to sugar source and test timing), has been shown to be 
reproducible in a group of ponies of unknown insulin dysregulation status 345. That same study 




bodyweight lead to similar insulin responses to glucose, which may make the test even more 
practical. When the same dose of glucose is administered by nasogastric tube 282, insulin 
dynamics appear to better correlate with data from the HEC and FSIGTT than the OST 39,321.  
 
Recent literature has also described a modified IFGT using nasogastric intubation as a delivery 
method for the glucose 361. This paper described higher cut-off values to separate horses with 
and without ID. The authors used a different insulin assay to that used in many other studies 
describing the IFGT (the Mercodia ELISA vs the Siemens Coat-A-Count RIA), however, making 
generalizability difficult to assess.  
 
As previously mentioned, the degree of post-CHO hyperinsulinaemia may be able to predict the 
risk of laminitis in a given period 91,99. As a patient-oriented outcome, this is likely of more use 
than cellular IR findings, which may not predict disease occurrence. In the Queensland study 91, 
one third of ponies that had insulin concentrations of 50-84 µU/mL after 1g/kg of in-feed glucose 
(i.e. lower than that used to diagnose ID) developed laminitis after exposure to a high NSC feed 
for a relatively short period of time. Thus, cut-offs used to diagnose ID, typically defined in certain 
populations, should be interpreted in light of predisposing factors present in any individual case. 
The Queensland study above described an algorithm for detecting insulin dysregulation which 
correlated well with subsequent development of laminitis 91, which is a potentially useful future 
diagnostic tool (Fig. 5.1). Importantly, those ponies who had post-sugar insulin concentrations of 
less than 50 µU/mL did not develop laminitis. 
 
The literature suggests that glucose is the main stimulus for insulin release in horses 77. The 
majority of glucose absorption occurs in the proximal small intestine and is mediated by SGLT1, 
GLUT2 and GLUT5 receptors 362 – thus, these receptors may be an area of future research. It may 
be that differences in expression or function of these receptors accounts for interindividual 
differences in insulin responses, and thus laminitis risk. Given the potential role of the 
enteroinsular axis in hyperinsulinaemia, antagonism of GIP 124 or GLP-1 125 may be an area of 




inhibition of SGLT2 363. This cotransporter is responsible for reabsorbing the majority of filtered 
glucose in the nephron. Inhibition of this reabsorption has been shown to both reduce glucose 
and insulin responses to high NSC diets, and more importantly, to prevent laminitis associated 
with this diet 363. 
 
 
FIGURE 5.1. A CLASSIFICATION AND REGRESSION TREE PREDICTING THE PROBABILITY OF LAMINITIS IN 37 PONIES BASED 
ON THE RETROSPECTIVE SERUM INSULIN CONCENTRATIONS FROM AN ORAL GLUCOSE SCREENING TEST PERFORMED 
DURING ENROLMENT (MODIFIED FROM MEIER ET AL. 2018  91). 
 
Another potential area of future research involves identifying factors leading to ID in subsets of 
PPID-affected horses. Specifically, it is unknown why some PPID horses might have ID but others 
not 141, despite otherwise similar signalment and management (i.e. independently from EMS). 
Whether it relates to individual POMC expression in diseased pituitaries 237, post-translational 





When TRH-stimulation tests were performed in a group of clinically normal horses with a low 
likelihood of PPID in two geographic locations in Australia during the quiescent phase of the 
circannual pituitary pars intermedia cycle, the ACTH concentrations were consistent with those 
previously reported for normal horses as confirmed by pituitary histology 180,236. This is of note as 
the reference intervals for baseline ACTH concentrations at these locations in Australia 210 differ 
from other locations (in the northern hemisphere) where the TRH-stimulated ACTH 
concentration cut-offs have been created 238. 
 
The results of the TRH-stimulation tests performed at March in Perth and April in Townsville 
suggest these time points are within the dynamic phase of the circannual pituitary cycle as 
marked variation in post-TRH ACTH concentrations occurs. Although a recent abstract 243 
suggested post-TRH cut-offs during the dynamic phase of the circannual pituitary cycle, the study 
numbers were small. Given the marked variability in endogenous ACTH concentrations after TRH 
stimulation in this study, further work is required to determine the results of TRH-stimulation 
testing in PPID horses during the dynamic phase of the circannual pituitary cycle. 
 
In the future, more specific ACTH assays may lead to more accurate diagnostic results, while 
further research into POMC post-translational handling or secretory defects may shed further 





Chapter 6. Epilogue 
It has previously been claimed that a ‘sugar conspiracy’ existed in the mid-to-late 20th century 
such that the sugar industry suppressed scientific research linking high sugar diets with human 
cardiovascular disease, and allegedly promoted low-fat diets instead 364. More recent research, 
however, has suggested that the rise of the low-fat diet was based on early epidemiologic studies 
into cardiovascular disease, in combination with unsubstantiated, but not dishonest, 
extrapolations in the media due to topical events 365. Further disproving inappropriate links 
between low-fat diet researchers and the food industry, Mark Hegsted, who was involved in 
research evaluating the effects of diet on cardiovascular disease, was fired by the Reagan 
administration for upsetting the US beef industry by claiming that the American diet was too high 
in protein 365. At the same time, John Yudkin discovered that sugar was linked to increased odds 
of cardiovascular disease, albeit based on small numbers 366.  
 
A sugar industry-sponsored review of dietary factors related to cardiovascular disease did 
emphasise fat as a cause of heart disease 367, but only because Hegsted did not believe there was, 
as yet, sufficient evidence to incriminate sugars 365. It should be noted that Yudkin himself, one 
of the only researchers investigating the link between sugar and cardiovascular disease, also 
received funding from industries that stood to benefit from his theories 365. Yudkin and Hegsted 
became rivals, with Yudkin ultimately losing when a working party of the British Medical Research 
Council found little evidence supporting his ideas 368. Hegsted also edited the US senate 
committee’s 1977 recommendations for dietary goals, emphasizing a low fat diet 365.  
 
Yudkin also had another vocal critic in Ancel Keys 369, an epidemiologist who showed, through an 
early example of ‘big data’, the correlation between high saturated fat intake and cardiovascular 
disease deaths 370. However, as this Seven Countries study continued into five decades, multiple 





While the evidence on dietary risk factors of cardiovascular disease is incomplete, it seems that 
the ‘sugar conspiracy’ actually reflects insufficient available evidence, together with personal 
rivalries, more than industry sabotage and unethical behaviour. 
 
It is interesting to speculate on the implications for equine laminitis had the link between sugar 
intake and cardiovascular disease been further emphasized 50 years ago, given the implications 
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Chapter 8. Appendices 
8.1 ACTH concentrations (pg/mL) before and 10 minutes after TRH 
administration in Perth 
September March 
Horse T0 T10 T0 T10 
43MU 25.4 52.4 40.1 117 
45MU 31 54.7 37.6 405 
46MU 28.4 47.8 54.0 352 
49MU 20.9 54.3 48.5 224 
50MU 27.8 69.7 49.7 254 
51MU 31.3 41.8 69.6 380 
52MU 30.3 56.3 51.7 146 
54MU 26.6 47.3 59.8 511 
55MU 33.7 46.2 35.6 251 
56MU 18.9 49.9 41.7 183 
57MU 22.3 54.6 45.6 114 
58MU 25.2 36 47.8 80 
59MU 24.7 57.4 63.3 213 
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8.2 ACTH concentrations (pg/mL) before and 30 minutes after TRH 
administration in Townsville 
September April 
Horse T0 T30 T0 T30 
7 27.3 62.4 51.9 127 
8 52.5 68 76.8 168 
9 16.3 27.2 39.4 141 
10 27.8 30.3 65.7 108 
13 35.3 22.9 74.1 82.1 
15 24.7 33.1 52.2 130 
17 29.9 35.4 49.8 57.5 
18 17.4 29.7 36.5 227 
19 32.2 50.5 86 101 
20 17.2 22.4 35.7 119 
22 23.2 35.4 59.2 76.6 
24 19.6 46.2 47.8 199 
25 23 32.2 29.3 78.1 
26 18.7 42.6 42.5 140 
28 29.6 42 45.7 150 
29 17.2 20.6 48.5 96.6 
30 20.8 27.6 85.9 79.7 
32 14.7 20.3 35 53.6 
35 16.9 37.3 25.6 101 
37 18.2 22.2 32 76.6 
38 18.5 18.1 35.4 87.1 
43 25.9 45 41 109 
44 25.2 39.4 37.1 75.5 
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8.3 Percentage increases in ACTH concentrations (pg/mL) after TRH 
administration in Perth and Townsville 
Perth Townsville 
Horse September March Horse September April 
43MU 106.30 191.77 7 128.57 144.70 
45MU 76.45 977.13 8 29.52381 118.75 
46MU 68.31 551.85 9 66.87 257.87 
49MU 159.81 361.86 10 8.99 64.38 
50MU 150.72 411.07 13 -35.13 10.80 
51MU 33.55 445.98 15 34.01 149.04 
52MU 85.81 182.40 17 18.39 15.46 
54MU 77.82 754.52 18 70.69 521.92 
55MU 37.09 605.06 19 56.83 17.44 
56MU 164.02 338.85 20 30.23 233.33 
57MU 144.84 150.00 22 52.59 29.39 
58MU 42.86 68.83 24 135.71 316.32 
59MU 132.39 236.49 25 40.00 166.55 
26 127.81 229.41 
28 41.89 228.23 
29 19.77 99.18 
30 32.69 -7.22
32 38.10 53.14 
35 120.71 294.53 
37 21.98 139.38 
38 -2.16 146.05 
43 73.75 165.85 
44 56.35 103.50 
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8.4 T30:T0 glucose ratios during the 2SIRT in treatment horses 
Week 1 Week 2 Week 3 
44MU 0.60 0.62 0.76 
46MU 0.38 0.72 
47MU 0.56 0.36 0.62 
49MU 0.50 0.71 
50MU 0.53 0.50 0.28 
51MU 1.06 0.66 0.39 
56MU 0.62 0.48 0.52 
59MU 0.30 0.31 0.33 
62MU 0.79 0.72 0.86 
64MU 0.57 0.50 0.82 
65MU 0.41 0.34 0.46 
67MU 0.75 
72MU 0.78 0.80 0.91 
73MU 0.70 0.46 0.34 
74MU 0.51 0.51 0.73 
8.5 Repeatability of the T30 timepoint glucose concentrations (mmol/L) as 
part of the 2SIRT 
8.5.1 Week 1 
Horse T25 T30 T35 
44MU 3.2 2.8 2.9 
46MU 2.8 2.7 
47MU 2.5 2.2 2.5 
49MU 1.5 
50MU 2.8 2.7 2.7 
51MU 3.5 3.3 
56MU 2.6 2.3 2.4 
59MU 1.2 1.1 2.2 
62MU 3.2 3.4 3.4 
64MU 3.4 2.4 2.4 
65MU 2.4 1.7 2.7 
67MU 3.8 3.6 3.5 
72MU 4.3 3.9 3.3 
73MU 2.8 2.6 2.3 
74MU 1.1 2 3.1 
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8.5.2 Week 2 
Horse T25 T30 T35 
44MU 2.3 2.6 2.9 
46MU 1.5 1.8 1.9 
47MU 1.9 1.4 1.8 
49MU 2.2 1.8 1.8 
50MU 2.3 1.8 1.6 
51MU 1.6 1.9 1.7 
56MU 2.3 2 1.6 
59MU 1.6 1.1 1.1 
62MU 2.6 2.8 3.3 
64MU 1.9 2.1 1.7 
65MU 1.7 1.3 1.2 
67MU 
72MU 3.2 4.1 3.7 
73MU 1.9 1.8 1.1 
74MU 2.2 1.8 1.8 
8.5.3 Week 3 
Horse T25 T30 T35 
44MU 3.3 3.4 2.8 
46MU 3.3 3.4 3.9 
47MU 2.6 3.2 3.5 
49MU 2.7 2.7 2.4 
50MU 4 1.1 1.1 
51MU 2 1.8 1.6 
56MU 2.6 2.2 2.1 
59MU 1.5 1.2 1.1 
62MU 3.2 3.6 3.4 
64MU 3.3 3.2 2.8 
65MU 2.3 2.2 1.8 
67MU 
72MU 3.8 4.2 3.9 
73MU 1.5 1.6 1.2 




8.6 Glucometer reliability assessed by random duplicate testing during the 
2SIRT (mmol/L) 
GLUC1 GLUC2 GLUC1 GLUC2 
4.7 4.3 3.9 3.4 
5.2 5.3 3.5 3.2 
3.8 3.9 2.3 2.2 
3.9 3.4 1.5 2.1 
4.6 4.4 1.9 1.9 
4.2 4 2.3 2.4 
3.6 3.6 2.3 1.9 
4.2 3.8 1.9 2.2 
3.9 4 1.4 1.4 
4.8 4.3 3.3 2.9 
4.6 4.7 1.7 1.6 
4.7 4.5 4.1 3.9 
4 4.1 3.7 3.4 
3.2 3.3 3.6 3.2 
1.5 1.3 3.7 3.7 
4.2 4.4 4.3 4.3 
4.8 4.7 4.1 4.1 
3.9 4.3 3.7 3.4 
3.6 3 3.2 3.7 
3.6 3.6 3.6 3.3 
2.9 2.8 4.8 4.2 
4.2 3.9 4.8 4.3 
3.5 3 4.7 4.8 
3.9 3.7 3.7 3.8 
4.2 4.2 3.9 3.6 





8.7 Endogenous ACTH concentrations (pg/mL) at T0 and T30 of the 2SIRT, 
organised by treatment group (sham vs real 2SIRT) 
Study ID Treatment T0 ACTH T30 ACTH 
43MU 0 24.1 32.5 
45MU 0 26.5 43.2 
48MU 0 36.5 29.8 
52MU 0 24.1 31.8 
53MU 0 20.7 34.4 
54MU 0 26.5 36.2 
55MU 0 23.2 21 
57MU 0 38.1 80.9 
63MU 0 24.9 24.7 
66MU 0 32.3 43 
68MU 0 30.2 32.1 
69MU 0 20.4 18.4 
70MU 0 25 32.3 
71MU 0 26.4 20 
75MU 0 27.7 25.4 
44MU 1 24.3 30.4 
46MU 1 23.6 40.3 
47MU 1 31.3 57.8 
49MU 1 24.4 24.4 
50MU 1 28.8 23.4 
51MU 1 32.6 29.3 
56MU 1 25.8 25.5 
59MU 1 22.6 29.3 
62MU 1 27.5 27.6 
64MU 1 33.8 42.6 
65MU 1 35.3 61.7 
67MU 1 35.5 39.1 
72MU 1 34.2 66.4 
73MU 1 26.7 20.9 
74MU 1 32.3 30.4 
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8.8 Insulin concentrations (µU/mL) during the OST in treatment horses 
Week 1 Week 2 Week 3 
 Horse T0 T60 T90 T0 T60 T90 T0 T60 T90 
44MU <2 4.32 5.26 <2 2.89 3.25 <2 2.56 3.87 
46MU <2 <2 2.48 <2 <2 <2 <2 <2 <2 
47MU <2 11.2 8.24 <2 4.89 2.53 <2 21.6 13.5 
49MU <2 <2 <2 <2 <2 <2 <2 <2 <2 
50MU <2 <2 <2 <2 2.04 3.44 <2 6.32 5.93 
51MU <2 <2 <2 <2 2.62 <2 <2 4.57 3.16 
56MU <2 <2 <2 <2 <2 <2 <2 <2 <2 
59MU <2 <2 <2 <2 <2 <2 <2 4.9 2.67 
62MU <2 <2 <2 <2 <2 <2 <2 <2 <2 
64MU <2 4.35 <2 <2 2.11 <2 <2 <2 2.36 
65MU <2 <2 <2 <2 2.81 <2 <2 <2 2.08 
76MU <2 26.2 13 <2 11.7 <2 <2 7.9 9.71 
72MU <2 <2 <2 <2 <2 9.06 <2 <2 2.61 
73MU <2 <2 <2 <2 5.99 4.45 <2 5.55 5.52 
74MU <2 6.85 3.33 <2 19.1 9.89 <2 22.4 12.7 
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8.9 Endogenous ACTH concentrations (pg/mL) at T0 and T60 of the OST, 
organised by treatment group (sham vs real OST) 
Study ID Treatment T0 ACTH T60 ACTH 
43MU 0 29.1 20.6 
45MU 0 25.2 18.2 
48MU 0 29.9 32 
52MU 0 23.9 27.3 
53MU 0 23.4 27.6 
54MU 0 27.5 36 
55MU 0 26.1 23 
57MU 0 30.2 53.9 
63MU 0 23 27.6 
66MU 0 21.8 15.6 
68MU 0 22.6 27.5 
69MU 0 32.9 22.6 
70MU 0 21.4 15.3 
71MU 0 30.6 20 
75MU 0 33.9 25.5 
44MU 1 22.9 33.8 
46MU 1 21.6 16.6 
47MU 1 46.5 26.5 
49MU 1 28.2 28.3 
50MU 1 28.3 33.6 
51MU 1 28.4 30.3 
56MU 1 33.3 21.6 
59MU 1 22.1 23.1 
62MU 1 29.5 42.8 
64MU 1 25.8 37.1 
65MU 1 28.3 108 
76MU 1 23.9 
72MU 1 35.8 51 
73MU 1 20 20.2 
74MU 1 24.1 26.3 
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8.10 Comparison of 2SIRT and OST by insulin dysregulation categorisation 
IRT OST 
Horse Week 1 Week 2 Week 3 Week 1 Week 2 Week 3 
44MU NO NO NO NO NO NO 
46MU YES YES NO NO NO NO 
47MU NO YES NO NO NO NO 
49MU YES NO NO NO NO NO 
50MU NO NO YES NO NO NO 
51MU NO NO YES NO NO NO 
56MU NO YES NO NO NO NO 
59MU YES YES YES NO NO NO 
62MU NO NO NO NO NO NO 
64MU NO NO NO NO NO NO 
65MU YES YES YES NO NO NO 
76MU NO YES YES NO NO NO 
72MU NO NO NO NO NO NO 
73MU NO YES YES NO NO NO 
74MU NO NO NO NO NO NO 
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‘Alle Ding sind Gift und nichts ohn' Gift; allein die Dosis macht, das ein Ding kein Gift ist 




‘Ah, there’s nothing more exciting than science. You get all the fun of sitting still, being 
quiet, writing down numbers, paying attention…..Science has it all.’ 
Principal Seymour Skinner, The Simpsons (1987-) 
‘til next time 
